Unnamed: 0 float64 0 700k | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher float64 | Author float64 | Article stringlengths 1 343k ⌀ | Lsa_summary stringlengths 48 53.9k ⌀ | Luhn_summary stringlengths 1 53.9k ⌀ | Textrank_summary stringlengths 1 53.9k ⌀ | Lexrank_summary stringlengths 1 53.9k ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|
25,200 | 2018-12-28 00:00:00 UTC | Friday Sector Leaders: Healthcare, Technology & Communications | ABBV | https://www.nasdaq.com/articles/friday-sector-leaders-healthcare-technology-communications-2018-12-28 | null | null | Looking at the sectors faring best as of midday Friday, shares of Healthcare companies are outperforming other sectors, up 0.8%. Within the sector, AbbVie Inc (Symbol: ABBV) and Bristol-Myers Squibb Co. (Symbol: BMY) are two large stocks leading the way, showing a gain of 2.5% and 2.4%, respectively. Among healthcare E... | Combined, ABBV and BMY make up approximately 6.8% of the underlying holdings of XLV. Within the sector, AbbVie Inc (Symbol: ABBV) and Bristol-Myers Squibb Co. (Symbol: BMY) are two large stocks leading the way, showing a gain of 2.5% and 2.4%, respectively. AbbVie Inc, meanwhile, is down 0.96% year-to-date, and Bristol... | Within the sector, AbbVie Inc (Symbol: ABBV) and Bristol-Myers Squibb Co. (Symbol: BMY) are two large stocks leading the way, showing a gain of 2.5% and 2.4%, respectively. AbbVie Inc, meanwhile, is down 0.96% year-to-date, and Bristol-Myers Squibb Co., is down 13.17% year-to-date. Combined, ABBV and BMY make up approx... | Within the sector, AbbVie Inc (Symbol: ABBV) and Bristol-Myers Squibb Co. (Symbol: BMY) are two large stocks leading the way, showing a gain of 2.5% and 2.4%, respectively. AbbVie Inc, meanwhile, is down 0.96% year-to-date, and Bristol-Myers Squibb Co., is down 13.17% year-to-date. Combined, ABBV and BMY make up approx... | Within the sector, AbbVie Inc (Symbol: ABBV) and Bristol-Myers Squibb Co. (Symbol: BMY) are two large stocks leading the way, showing a gain of 2.5% and 2.4%, respectively. AbbVie Inc, meanwhile, is down 0.96% year-to-date, and Bristol-Myers Squibb Co., is down 13.17% year-to-date. Combined, ABBV and BMY make up approx... |
25,201 | 2018-12-28 00:00:00 UTC | Noteworthy ETF Inflows: SDY, O, NNN, ABBV | ABBV | https://www.nasdaq.com/articles/noteworthy-etf-inflows-sdy-o-nnn-abbv-2018-12-28 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Dividend ETF (Symbol: SDY) where we have detected an approximate $479.7 million dollar inflow -- that's a 3.1% increase week over week in outstanding units (from 172,650,000 to 178... | Among the largest underlying components of SDY, in trading today Realty Income Corp (Symbol: O) is up about 0.4%, National Retail Properties Inc (Symbol: NNN) is up about 0.2%, and AbbVie Inc (Symbol: ABBV) is up by about 0.7%. For a complete list of holdings, visit the SDY Holdings page » The chart below shows the one... | Among the largest underlying components of SDY, in trading today Realty Income Corp (Symbol: O) is up about 0.4%, National Retail Properties Inc (Symbol: NNN) is up about 0.2%, and AbbVie Inc (Symbol: ABBV) is up by about 0.7%. For a complete list of holdings, visit the SDY Holdings page » The chart below shows the one... | Among the largest underlying components of SDY, in trading today Realty Income Corp (Symbol: O) is up about 0.4%, National Retail Properties Inc (Symbol: NNN) is up about 0.2%, and AbbVie Inc (Symbol: ABBV) is up by about 0.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covere... | Among the largest underlying components of SDY, in trading today Realty Income Corp (Symbol: O) is up about 0.4%, National Retail Properties Inc (Symbol: NNN) is up about 0.2%, and AbbVie Inc (Symbol: ABBV) is up by about 0.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covere... |
25,202 | 2018-12-28 00:00:00 UTC | Will AbbVie (ABBV) Shares Regain Lost Momentum in 2019? | ABBV | https://www.nasdaq.com/articles/will-abbvie-abbv-shares-regain-lost-momentum-in-2019-2018-12-28 | null | null | AbbVie, Inc .'s ABBV stock has declined 7% this year so far against an increase of 2.1% recorded by the industry .
A couple of pipeline setbacks as well as concerns about the impact of EU biosimilar launches on sales of its blockbuster drug Humira hurt the stock this year despite several regulatory approvals and pipeli... | In March, Rova-T fell short of expectations in a phase II TRINITY study evaluating it in third line or later SCLC.Rova-T was added to AbbVie's portfolio following the $5.8 billion acquisition of Stemcentrx in June 2016. In October, AbbVie had said it is confident of delivering double-digit earnings growth in 2019 despi... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie, Inc . 's ABBV stock has declined 7% this year so far... | In October, AbbVie had said it is confident of delivering double-digit earnings growth in 2019 despite negative impact from EU Humira biosimilar entry, a difficult comparison year (as HCV sales ramped up rapidly in 2018) and significant investments to support product launches. Click to get this free report AbbVie Inc. ... | AbbVie, Inc . 's ABBV stock has declined 7% this year so far against an increase of 2.1% recorded by the industry . In early December, AbbVie stopped enrolment in a late-stage study, TAHOE , evaluating its cancer candidate rovalpituzumab tesirine or Rova-T in second-line small cell lung cancer (SCLC). |
25,203 | 2018-12-27 00:00:00 UTC | ABBV February 2019 Options Begin Trading | ABBV | https://www.nasdaq.com/articles/abbv-february-2019-options-begin-trading-2018-12-27 | null | null | Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the February 2019 expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ABBV options chain for the new February 2019 contracts and identified one put and one call contract of particular interest.
The put c... | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the... | Below is a chart showing ABBV's trailing twelve month trading history, with the $93.00 strike highlighted in red: Considering the fact that the $93.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possi... | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $87.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $93.00 strike price has a current bid of $1.67. Below is a chart showing ABBV'... | At Stock Options Channel , our YieldBoost formula has looked up and down the ABBV options chain for the new February 2019 contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $93.00 strike highlighted in red: Consi... |
25,204 | 2018-12-27 00:00:00 UTC | AbbVie Stock: 3 Pros and 3 Cons to Consider Before Investing in ABBV | ABBV | https://www.nasdaq.com/articles/abbvie-stock-3-pros-and-3-cons-consider-investing-abbv-2018-12-27 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
When most people think about cannabis stocks, AbbVie (NYSE: ABBV ) doesn't immediately come to mind. But thanks to its cannabis-based drug Marinol, ABBV stock offers indirect exposure to the marijuana industry. Perhaps that's partially why shares jumped ove... | Pro #3: Business-first Mentality Boosts AbbVie Stock A recent Bloomberg article had an interesting take on Gilead Sciences (NASDAQ: GILD ). I don't necessarily agree that Gilead made a business mistake, but one thing is clear: ABBV's focus on growth and profitability benefits AbbVie stock. InvestorPlace - Stock Market ... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips When most people think about cannabis stocks, AbbVie (NYSE: ABBV ) doesn't immediately come to mind. Despite the ABBV stock price today, shares are down nearly double digits for the year. With the ABBV stock price today, the pharma giant pays out 4.81%. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips When most people think about cannabis stocks, AbbVie (NYSE: ABBV ) doesn't immediately come to mind. Con #2: AbbVie Stock has a PR Problem Humira is a top seller, but that metric alone hasn't prevented AbbVie stock from attracting unwanted attention. More F... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips When most people think about cannabis stocks, AbbVie (NYSE: ABBV ) doesn't immediately come to mind. More From InvestorPlace 2 Toxic Pot Stocks You Should Avoid 10 Small-Cap Stocks That Look Like Bargains 7 Stocks to Buy and Hold Through Any Market Selloff ... |
25,205 | 2018-12-26 00:00:00 UTC | AbbVie Partners Lupin to Boost Hematological Cancer Pipeline | ABBV | https://www.nasdaq.com/articles/abbvie-partners-lupin-to-boost-hematological-cancer-pipeline-2018-12-26 | null | null | AbbVie Inc.ABBV and India-based Lupin Limited announced a partnership to develop and commercialize a novel cancer drug for the treatment of hematological cancer. The partnership grants AbbVie exclusive global rights to develop and commercialize Lupin's MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Pro... | The partnership grants AbbVie exclusive global rights to develop and commercialize Lupin's MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitor program. AbbVie is planning to develop the MALT1 inhibitors across a range of hematological cancers, the majority of them with limited treatment... | AbbVie has several collaborations for developing its cancer pipeline, which include one with Roche RHHBY for Venclexta, Johnson & Johnson JNJ for Imbruvica and Bristol-Myers BMY for Empliciti among others. AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Zacks Rank AbbVie currently carries a Zacks Rank #3 (Hold)... | AbbVie Inc.ABBV and India-based Lupin Limited announced a partnership to develop and commercialize a novel cancer drug for the treatment of hematological cancer. AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Zacks Rank AbbVie currently carries a Zacks Rank #3 (Hold). Click to get this free report Johnson & Jo... | AbbVie Inc.ABBV and India-based Lupin Limited announced a partnership to develop and commercialize a novel cancer drug for the treatment of hematological cancer. Meanwhile, AbbVie has a few oncology drugs in its marketed portfolio. The partnership grants AbbVie exclusive global rights to develop and commercialize Lupin... |
25,206 | 2018-12-26 00:00:00 UTC | Health Care Sector Update for 12/26/2018: CAPR,IMMU,ABBV,NEOS,TEVA | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-12262018-caprimmuabbvneosteva-2018-12-26 | null | null | Top Health Care Stocks
JNJ +2.51%
PFE +3.63%
ABT +5.58%
MRK +3.56%
AMGN +4.61%
Health care stocks were posting strong gains Wednesday afternoon, including a more than 2.6% rise for the NYSE Health Care Index in late trade. Shares of health care companies in the S&P 500 also were up over 3.7% as a group while the Nasdaq... | (+) AbbVie ( ABBV ) was more than 3% higher Wednesday after Standpoint Research began coverage of the drugmaker with a buy investment recommendation. Among health care stocks moving on news: (-) Capricor Therapeutics ( CAPR ) slid 26% to a record low of 33 cents a share on Wednesday, and later received a downgrade to h... | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (+) AbbVie ( ABBV ) was more than 3% higher Wednesday after Standpoint Research began coverage of the drugmaker with a buy investment recommendation. Shares of health care companies in t... | (+) AbbVie ( ABBV ) was more than 3% higher Wednesday after Standpoint Research began coverage of the drugmaker with a buy investment recommendation. Health care stocks were posting strong gains Wednesday afternoon, including a more than 2.6% rise for the NYSE Health Care Index in late trade. Among health care stocks m... | (+) AbbVie ( ABBV ) was more than 3% higher Wednesday after Standpoint Research began coverage of the drugmaker with a buy investment recommendation. Top Health Care Stocks In other sector news: (+) Immunomedics ( IMMU ) rose as much as 13% on Wednesday after the biopharmaceuticals company said it was expanding its lon... |
25,207 | 2018-12-24 00:00:00 UTC | AbbVie (ABBV) Stock Moves -0.89%: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-stock-moves-0.89%3A-what-you-should-know-2018-12-24 | null | null | AbbVie (ABBV) closed the most recent trading day at $84.16, moving -0.89% from the previous trading session. This move was narrower than the S&P 500's daily loss of 2.71%. Meanwhile, the Dow lost 2.91%, and the Nasdaq, a tech-heavy index, lost 2.21%.
Prior to today's trading, shares of the drugmaker had lost 1.43% over... | AbbVie (ABBV) closed the most recent trading day at $84.16, moving -0.89% from the previous trading session. Wall Street will be looking for positivity from ABBV as it approaches its next earnings report date. It is also important to note the recent changes to analyst estimates for ABBV. | AbbVie (ABBV) closed the most recent trading day at $84.16, moving -0.89% from the previous trading session. Wall Street will be looking for positivity from ABBV as it approaches its next earnings report date. It is also important to note the recent changes to analyst estimates for ABBV. | AbbVie (ABBV) closed the most recent trading day at $84.16, moving -0.89% from the previous trading session. Wall Street will be looking for positivity from ABBV as it approaches its next earnings report date. It is also important to note the recent changes to analyst estimates for ABBV. | AbbVie (ABBV) closed the most recent trading day at $84.16, moving -0.89% from the previous trading session. Wall Street will be looking for positivity from ABBV as it approaches its next earnings report date. It is also important to note the recent changes to analyst estimates for ABBV. |
25,208 | 2018-12-22 00:00:00 UTC | Better Buy: AbbVie vs. Merck | ABBV | https://www.nasdaq.com/articles/better-buy-abbvie-vs-merck-2018-12-22 | null | null | What a difference a year can make. In 2017, shares of AbbVie (NYSE: ABBV) skyrocketed more than 50%, while Merck (NYSE: MRK) stock fell 4%. But so far this year, Merck is a big winner, while AbbVie is down by a double-digit percentage.
And none of that matters very much when it comes to choosing which of these big-phar... | It didn't help that AbbVie also experienced a significant pipeline setback this year with disappointing clinical results for experimental cancer drug Rova-T. Because of AbbVie's solid current lineup and pipeline, Wall Street analysts project the company will grow earnings by nearly 17% annually on average over the next... | The primary reason why AbbVie stock hasn't performed very well in 2018 relates to concerns about biosimilar competition for AbbVie's top-selling drug, Humira. Because of AbbVie's solid current lineup and pipeline, Wall Street analysts project the company will grow earnings by nearly 17% annually on average over the nex... | The primary reason why AbbVie stock hasn't performed very well in 2018 relates to concerns about biosimilar competition for AbbVie's top-selling drug, Humira. Because of Merck's big run this year, though, its stock isn't as attractively valued as AbbVie's. In 2017, shares of AbbVie (NYSE: ABBV) skyrocketed more than 50... | That level of growth makes AbbVie stock look like a bargain, with shares trading at less than 10 times expected earnings. Because of Merck's big run this year, though, its stock isn't as attractively valued as AbbVie's. In 2017, shares of AbbVie (NYSE: ABBV) skyrocketed more than 50%, while Merck (NYSE: MRK) stock fell... |
25,209 | 2018-12-21 00:00:00 UTC | Alector, Gossamer chase Moderna with biotechnology IPOs | ABBV | https://www.nasdaq.com/articles/alector-gossamer-chase-moderna-biotechnology-ipos-2018-12-21 | null | null | By Joshua Franklin and Carl O'Donnell
Dec 21 () - U.S. biotechnology startups Alector LLC and Gossamer Bio are preparing for initial public offerings (IPOs) in early 2019, people familiar with the matter said on Friday, after Moderna Inc earlier this month became the sector's biggest company to ever launch an IPO.
Comp... | It has received backing from the likes of Google Ventures and AbbVie Inc and closed its series E funding round earlier this year with a $913 million raise, according to PitchBook. By Joshua Franklin and Carl O'Donnell Dec 21 () - U.S. biotechnology startups Alector LLC and Gossamer Bio are preparing for initial public ... | It has received backing from the likes of Google Ventures and AbbVie Inc and closed its series E funding round earlier this year with a $913 million raise, according to PitchBook. Companies have been accelerating their IPO preparations, as a stock market sell-off in the last three months wiped out the gains of most sha... | It has received backing from the likes of Google Ventures and AbbVie Inc and closed its series E funding round earlier this year with a $913 million raise, according to PitchBook. By Joshua Franklin and Carl O'Donnell Dec 21 () - U.S. biotechnology startups Alector LLC and Gossamer Bio are preparing for initial public ... | It has received backing from the likes of Google Ventures and AbbVie Inc and closed its series E funding round earlier this year with a $913 million raise, according to PitchBook. Companies have been accelerating their IPO preparations, as a stock market sell-off in the last three months wiped out the gains of most sha... |
25,210 | 2018-12-21 00:00:00 UTC | AbbVie (ABBV) Seeks Approval for RA Candidate Upadacitinib | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-seeks-approval-for-ra-candidate-upadacitinib-2018-12-21 | null | null | AbbVie Inc.ABBV announced that it has filed a new drug application ("NDA") to the FDA and a marketing authorization application ("MAA") to the European Medicines Agency ("EMA") for its oral investigational JAK inhibitor, upadacitinib. The company is seeking approval of upadacitinib for the treatment of adult patients w... | AbbVie Inc.ABBV announced that it has filed a new drug application ("NDA") to the FDA and a marketing authorization application ("MAA") to the European Medicines Agency ("EMA") for its oral investigational JAK inhibitor, upadacitinib. Shares of AbbVie were up 2.2%, following the announcement of the news of Thursday. Hu... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc.ABBV announced that it has filed a new drug app... | AbbVie Inc.ABBV announced that it has filed a new drug application ("NDA") to the FDA and a marketing authorization application ("MAA") to the European Medicines Agency ("EMA") for its oral investigational JAK inhibitor, upadacitinib. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer I... | AbbVie Inc.ABBV announced that it has filed a new drug application ("NDA") to the FDA and a marketing authorization application ("MAA") to the European Medicines Agency ("EMA") for its oral investigational JAK inhibitor, upadacitinib. Shares of AbbVie were up 2.2%, following the announcement of the news of Thursday. Hu... |
25,211 | 2018-12-21 00:00:00 UTC | Noteworthy Friday Option Activity: CLVS, ABBV, AAL | ABBV | https://www.nasdaq.com/articles/noteworthy-friday-option-activity-clvs-abbv-aal-2018-12-21 | null | null | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Clovis Oncology Inc (Symbol: CLVS), where a total volume of 16,911 contracts has been traded thus far today, a contract volume which is representative of approximately 1.7 million underlying shares (giv... | Particularly high volume was seen for the $95 strike call option expiring January 18, 2019 , with 4,233 contracts trading so far today, representing approximately 423,300 underlying shares of ABBV. Below is a chart showing CLVS's trailing twelve month trading history, with the $22.50 strike highlighted in orange: AbbVi... | Below is a chart showing CLVS's trailing twelve month trading history, with the $22.50 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) saw options trading volume of 28,094 contracts, representing approximately 2.8 million underlying shares or approximately 48.1% of ABBV's average daily trading volume over the p... | Below is a chart showing CLVS's trailing twelve month trading history, with the $22.50 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) saw options trading volume of 28,094 contracts, representing approximately 2.8 million underlying shares or approximately 48.1% of ABBV's average daily trading volume over the p... | Below is a chart showing CLVS's trailing twelve month trading history, with the $22.50 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) saw options trading volume of 28,094 contracts, representing approximately 2.8 million underlying shares or approximately 48.1% of ABBV's average daily trading volume over the p... |
25,212 | 2018-12-20 00:00:00 UTC | Notable ETF Inflow Detected - XLV, ABBV, ABT, CVS | ABBV | https://www.nasdaq.com/articles/notable-etf-inflow-detected-xlv-abbv-abt-cvs-2018-12-20 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $520.3 million dollar inflow -- that's a 2.9% increase week over week in outstanding units (from 209,... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.6%, Abbott Laboratories (Symbol: ABT) is off about 1.4%, and CVS Health Corporation (Symbol: CVS) is lower by about 1.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.6%, Abbott Laboratories (Symbol: ABT) is off about 1.4%, and CVS Health Corporation (Symbol: CVS) is lower by about 1.2%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one ... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.6%, Abbott Laboratories (Symbol: ABT) is off about 1.4%, and CVS Health Corporation (Symbol: CVS) is lower by about 1.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.6%, Abbott Laboratories (Symbol: ABT) is off about 1.4%, and CVS Health Corporation (Symbol: CVS) is lower by about 1.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered... |
25,213 | 2018-12-20 00:00:00 UTC | 3 Top Healthcare Stocks to Buy in December | ABBV | https://www.nasdaq.com/articles/3-top-healthcare-stocks-buy-december-2018-12-20 | null | null | The recent market downturn has created lots of bargains for healthcare-focused investors. So which stocks do our team of healthcare contributors think are great buys right now?
We posed that very question to our team, and they called out the SPDR S&P Biotech ETF (NYSEMKT: XBI) , AbbVie (NYSE: ABBV) , and Jazz Pharmaceu... | We posed that very question to our team, and they called out the SPDR S&P Biotech ETF (NYSEMKT: XBI) , AbbVie (NYSE: ABBV) , and Jazz Pharmaceuticals (NASDAQ: JAZZ) . Hitting the trifecta Keith Speights (AbbVie): Probably the best equivalent to a trifecta in investing is finding a stock that provides solid income, grea... | We posed that very question to our team, and they called out the SPDR S&P Biotech ETF (NYSEMKT: XBI) , AbbVie (NYSE: ABBV) , and Jazz Pharmaceuticals (NASDAQ: JAZZ) . Keith Speights owns shares of AbbVie, Gilead Sciences, and SPDR S&P Biotech. Hitting the trifecta Keith Speights (AbbVie): Probably the best equivalent t... | We posed that very question to our team, and they called out the SPDR S&P Biotech ETF (NYSEMKT: XBI) , AbbVie (NYSE: ABBV) , and Jazz Pharmaceuticals (NASDAQ: JAZZ) . Hitting the trifecta Keith Speights (AbbVie): Probably the best equivalent to a trifecta in investing is finding a stock that provides solid income, grea... | But AbbVie does. We posed that very question to our team, and they called out the SPDR S&P Biotech ETF (NYSEMKT: XBI) , AbbVie (NYSE: ABBV) , and Jazz Pharmaceuticals (NASDAQ: JAZZ) . Hitting the trifecta Keith Speights (AbbVie): Probably the best equivalent to a trifecta in investing is finding a stock that provides s... |
25,214 | 2018-12-19 00:00:00 UTC | Why Eli Lilly Stock Is Still Shining in the Darkness | ABBV | https://www.nasdaq.com/articles/why-eli-lilly-stock-still-shining-darkness-2018-12-19 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
While the average S&P 500 stock has corrected with the market average down 13% in three months, shares in Eli Lilly (NYSE: LLY ) have stood strong, and were due for a nice pop when trade opened Dec. 19. There has been a pronounced turn to big drug stocks am... | It says its Taltz , an immunosuppressant used against psoriasis, topped AbbVie (NYSE: ABBV ) market leader Humira in a recent study, delivering more symptom improvement. Lilly's pipeline includes late-stage drugs against cancer, diabetes and in immunology, as well as against pain, and it expects new medicines like Talt... | It says its Taltz , an immunosuppressant used against psoriasis, topped AbbVie (NYSE: ABBV ) market leader Humira in a recent study, delivering more symptom improvement. InvestorPlace - Stock Market News, Stock Advice & Trading Tips While the average S&P 500 stock has corrected with the market average down 13% in three... | It says its Taltz , an immunosuppressant used against psoriasis, topped AbbVie (NYSE: ABBV ) market leader Humira in a recent study, delivering more symptom improvement. InvestorPlace - Stock Market News, Stock Advice & Trading Tips While the average S&P 500 stock has corrected with the market average down 13% in three... | It says its Taltz , an immunosuppressant used against psoriasis, topped AbbVie (NYSE: ABBV ) market leader Humira in a recent study, delivering more symptom improvement. LLY stock itself is also delivering some welcome good news. This starts with a 15% hike in the dividend, to 64.5 cents per share, and a prediction fro... |
25,215 | 2018-12-19 00:00:00 UTC | Eli Lilly sees 2019 profit, revenue above estimates; shares rise | ABBV | https://www.nasdaq.com/articles/eli-lilly-sees-2019-profit-revenue-above-estimates-shares-rise-2018-12-19 | null | null | Dec 19 () - Eli Lilly and Co on Wednesday forecast better-than-expected revenue and adjusted profit for 2019, as the drugmaker benefits from higher demand for its newer medicines including diabetes drug Trulicity and psoriasis drug Taltz.
Shares of the company, which raised its quarterly dividend by 15 percent, rose 3.... | The company earlier this month said Taltz was found to be more effective in improving symptoms of psoriatic arthritis when compared to AbbVie Inc's Humira, the world's best selling prescription medicine. Trulicity, for instance, recently overtook Humalog to become Lilly's top-selling medicine with sales of $816.2 milli... | The company earlier this month said Taltz was found to be more effective in improving symptoms of psoriatic arthritis when compared to AbbVie Inc's Humira, the world's best selling prescription medicine. Dec 19 () - Eli Lilly and Co on Wednesday forecast better-than-expected revenue and adjusted profit for 2019, as the... | The company earlier this month said Taltz was found to be more effective in improving symptoms of psoriatic arthritis when compared to AbbVie Inc's Humira, the world's best selling prescription medicine. Dec 19 () - Eli Lilly and Co on Wednesday forecast better-than-expected revenue and adjusted profit for 2019, as the... | The company earlier this month said Taltz was found to be more effective in improving symptoms of psoriatic arthritis when compared to AbbVie Inc's Humira, the world's best selling prescription medicine. Dec 19 () - Eli Lilly and Co on Wednesday forecast better-than-expected revenue and adjusted profit for 2019, as the... |
25,216 | 2018-12-18 00:00:00 UTC | Lilly's Taltz Outshines Humira in Psoriatic Arthritis Study | ABBV | https://www.nasdaq.com/articles/lillys-taltz-outshines-humira-in-psoriatic-arthritis-study-2018-12-18 | null | null | Eli Lilly & Company 's LLY drug Taltz demonstrated superiority in improving the signs and symptoms of active psoriatic arthritis (PsA) while also providing skin clearance in a head-to-head study comparing it with AbbVie, Inc.'s ABBV blockbuster medicine Humira.
The primary endpoint of the phase IIb/IV study - SPIRIT-H2... | Eli Lilly & Company 's LLY drug Taltz demonstrated superiority in improving the signs and symptoms of active psoriatic arthritis (PsA) while also providing skin clearance in a head-to-head study comparing it with AbbVie, Inc.'s ABBV blockbuster medicine Humira. Click to get this free report AbbVie Inc. (ABBV): Free Sto... | Eli Lilly & Company 's LLY drug Taltz demonstrated superiority in improving the signs and symptoms of active psoriatic arthritis (PsA) while also providing skin clearance in a head-to-head study comparing it with AbbVie, Inc.'s ABBV blockbuster medicine Humira. Click to get this free report AbbVie Inc. (ABBV): Free Sto... | Eli Lilly & Company 's LLY drug Taltz demonstrated superiority in improving the signs and symptoms of active psoriatic arthritis (PsA) while also providing skin clearance in a head-to-head study comparing it with AbbVie, Inc.'s ABBV blockbuster medicine Humira. Click to get this free report AbbVie Inc. (ABBV): Free Sto... | Eli Lilly & Company 's LLY drug Taltz demonstrated superiority in improving the signs and symptoms of active psoriatic arthritis (PsA) while also providing skin clearance in a head-to-head study comparing it with AbbVie, Inc.'s ABBV blockbuster medicine Humira. Click to get this free report AbbVie Inc. (ABBV): Free Sto... |
25,217 | 2018-12-18 00:00:00 UTC | The Zacks Analyst Blog Highlights: McDonald???s, AbbVie, Altria, Wells Fargo and Disney | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-mcdonalds-abbvie-altria-wells-fargo-and-disney-2018-12 | null | null | For Immediate Release
Chicago, IL -December 18, 2018 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: McDonald's MCD , AbbVie AB... | Stocks recently featured in the blog include: McDonald's MCD , AbbVie ABBV , Altria MO , Wells Fargo WFC and Disney DIS . The Zacks analyst likes the fact that AbbVie's key drug, Humira, has been performing well based on strong demand trends despite new competition. Here are highlights from Monday's Analyst Blog: Top S... | Stocks recently featured in the blog include: McDonald's MCD , AbbVie ABBV , Altria MO , Wells Fargo WFC and Disney DIS . Today's Research Daily features new research reports on 16 major stocks, including McDonald's, AbbVie and Altria. Click to get this free report Wells Fargo & Company (WFC): Free Stock Analysis Repor... | Here are highlights from Monday's Analyst Blog: Top Stock Reports for McDonald's, AbbVie and Altria The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including McDonald's, AbbVie and Altria. Click to get this free rep... | Here are highlights from Monday's Analyst Blog: Top Stock Reports for McDonald's, AbbVie and Altria The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including McDonald's, AbbVie and Altria. AbbVie expects to launch m... |
25,218 | 2018-12-17 00:00:00 UTC | Lilly says Taltz superior to Humira in late-stage psoriatic arthritis trial | ABBV | https://www.nasdaq.com/articles/lilly-says-taltz-superior-humira-late-stage-psoriatic-arthritis-trial-2018-12-17 | null | null | By Tamara Mathias
Dec 17 () - Eli Lilly and Co said on Monday its psoriatic arthritis drug, Taltz, was found to be more effective than the world's best-selling prescription medicine, AbbVie Inc's Humira, in a late-stage trial.
The trial was the first of its kind to test Taltz and the standard-of-care, Humira, head-to-h... | By Tamara Mathias Dec 17 () - Eli Lilly and Co said on Monday its psoriatic arthritis drug, Taltz, was found to be more effective than the world's best-selling prescription medicine, AbbVie Inc's Humira, in a late-stage trial. Humira has been the top-earner for AbbVie since the company was spun off from medical device ... | By Tamara Mathias Dec 17 () - Eli Lilly and Co said on Monday its psoriatic arthritis drug, Taltz, was found to be more effective than the world's best-selling prescription medicine, AbbVie Inc's Humira, in a late-stage trial. Humira has been the top-earner for AbbVie since the company was spun off from medical device ... | By Tamara Mathias Dec 17 () - Eli Lilly and Co said on Monday its psoriatic arthritis drug, Taltz, was found to be more effective than the world's best-selling prescription medicine, AbbVie Inc's Humira, in a late-stage trial. Humira has been the top-earner for AbbVie since the company was spun off from medical device ... | By Tamara Mathias Dec 17 () - Eli Lilly and Co said on Monday its psoriatic arthritis drug, Taltz, was found to be more effective than the world's best-selling prescription medicine, AbbVie Inc's Humira, in a late-stage trial. Humira has been the top-earner for AbbVie since the company was spun off from medical device ... |
25,219 | 2018-12-17 00:00:00 UTC | AbbVie (ABBV) Stock Moves -0.79%: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-stock-moves-0.79%3A-what-you-should-know-2018-12-17 | null | null | In the latest trading session, AbbVie (ABBV) closed at $84.93, marking a -0.79% move from the previous day. This change was narrower than the S&P 500's daily loss of 2.08%. Elsewhere, the Dow lost 2.11%, while the tech-heavy Nasdaq lost 2.27%.
Heading into today, shares of the drugmaker had lost 5.03% over the past mon... | In the latest trading session, AbbVie (ABBV) closed at $84.93, marking a -0.79% move from the previous day. ABBV will be looking to display strength as it nears its next earnings release, which is expected to be January 25, 2019. On that day, ABBV is projected to report earnings of $1.92 per share, which would represen... | In the latest trading session, AbbVie (ABBV) closed at $84.93, marking a -0.79% move from the previous day. ABBV will be looking to display strength as it nears its next earnings release, which is expected to be January 25, 2019. On that day, ABBV is projected to report earnings of $1.92 per share, which would represen... | In the latest trading session, AbbVie (ABBV) closed at $84.93, marking a -0.79% move from the previous day. ABBV will be looking to display strength as it nears its next earnings release, which is expected to be January 25, 2019. On that day, ABBV is projected to report earnings of $1.92 per share, which would represen... | In the latest trading session, AbbVie (ABBV) closed at $84.93, marking a -0.79% move from the previous day. ABBV will be looking to display strength as it nears its next earnings release, which is expected to be January 25, 2019. On that day, ABBV is projected to report earnings of $1.92 per share, which would represen... |
25,220 | 2018-12-16 00:00:00 UTC | Validea's Top Five Healthcare Stocks Based On John Neff - 12/16/2018 | ABBV | https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-john-neff-12162018-2018-12-16 | null | null | The following are the top rated Healthcare stocks according to Validea's Low PE Investor model based on the published strategy of John Neff . This strategy looks for firms with persistent earnings growth that trade at a discount relative to their earnings growth and dividend yield.
ABBVIE INC ( ABBV ) is a large-cap gr... | ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The following are the top rated Healthcare stocks according to Validea's Low PE Investor model based on the published strategy of John Neff . | ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. For a full detailed analysis using NASDAQ's Guru Analysis tool, click here AMERISOURCEBERGEN CORP. ( ABC ) is a large-cap growth stock in the Bi... | ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Met... | ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company's segments include Pharmaceutical Distribution and Other. |
25,221 | 2018-12-12 00:00:00 UTC | Notable ETF Outflow Detected - XLV, ABBV, ABT, CVS | ABBV | https://www.nasdaq.com/articles/notable-etf-outflow-detected-xlv-abbv-abt-cvs-2018-12-12 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $122.7 million dollar outflow -- that's a 0.6% decrease week over week (from 211,265,324 to 209,920,0... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 2%, Abbott Laboratories (Symbol: ABT) is up about 2.1%, and CVS Health Corporation (Symbol: CVS) is higher by about 1.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered a... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 2%, Abbott Laboratories (Symbol: ABT) is up about 2.1%, and CVS Health Corporation (Symbol: CVS) is higher by about 1.5%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one ye... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 2%, Abbott Laboratories (Symbol: ABT) is up about 2.1%, and CVS Health Corporation (Symbol: CVS) is higher by about 1.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered a... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 2%, Abbott Laboratories (Symbol: ABT) is up about 2.1%, and CVS Health Corporation (Symbol: CVS) is higher by about 1.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered a... |
25,222 | 2018-12-12 00:00:00 UTC | 5 Pharma Stocks That Could Cure Ailing Portfolios in 2019 | ABBV | https://www.nasdaq.com/articles/5-pharma-stocks-that-could-cure-ailing-portfolios-in-2019-2018-12-12 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
The pharmaceutical sector delivers two benefits that appeal to investors: reasonable P/E ratios and growth catalysts. Many pharma stocks have suffered as of late. Some have key drugs facing patent expirations. Meanwhile, others have sold off as trade-relate... | The 10 Best Marijuana Stocks to Buy in 2019 The following five pharma stocks appear particularly well-positioned to benefit from new drugs and demographic tailwinds in 2019: AbbVie (ABBV) Source: Shutterstock AbbVie (NYSE: ABBV ) has sold off in recent months as concerns about losing the patent on Humira and trade-war ... | The 10 Best Marijuana Stocks to Buy in 2019 The following five pharma stocks appear particularly well-positioned to benefit from new drugs and demographic tailwinds in 2019: AbbVie (ABBV) Source: Shutterstock AbbVie (NYSE: ABBV ) has sold off in recent months as concerns about losing the patent on Humira and trade-war ... | The 10 Best Marijuana Stocks to Buy in 2019 The following five pharma stocks appear particularly well-positioned to benefit from new drugs and demographic tailwinds in 2019: AbbVie (ABBV) Source: Shutterstock AbbVie (NYSE: ABBV ) has sold off in recent months as concerns about losing the patent on Humira and trade-war ... | The 10 Best Marijuana Stocks to Buy in 2019 The following five pharma stocks appear particularly well-positioned to benefit from new drugs and demographic tailwinds in 2019: AbbVie (ABBV) Source: Shutterstock AbbVie (NYSE: ABBV ) has sold off in recent months as concerns about losing the patent on Humira and trade-war ... |
25,223 | 2018-12-12 00:00:00 UTC | 3 Beaten-Down Biotech Stocks That Could Bounce Back in 2019 | ABBV | https://www.nasdaq.com/articles/3-beaten-down-biotech-stocks-could-bounce-back-2019-2018-12-12 | null | null | Developing new drugs is a risky business that hasn't been kind to these three biotechs or their shareholders lately. But despite recent tumbling stock prices, all of these companies have a chance to bounce back in 2019.
Of course, some of these biotech stocks have a better chance than others. Here's what you need to kn... | Ublituximab and Gazyva both target CD20, and TG investors should be nervous about a treatment that AbbVie (NYSE: ABBV) already markets with great success. AbbVie's Venclexta plus Rituxan blew the doors off Rituxan plus chemo for a group of patients similar to those enrolled in the Unity study. TG Therapeutics: Tough ac... | Ublituximab and Gazyva both target CD20, and TG investors should be nervous about a treatment that AbbVie (NYSE: ABBV) already markets with great success. AbbVie's Venclexta plus Rituxan blew the doors off Rituxan plus chemo for a group of patients similar to those enrolled in the Unity study. Madrigal Pharmaceuticals:... | Ublituximab and Gazyva both target CD20, and TG investors should be nervous about a treatment that AbbVie (NYSE: ABBV) already markets with great success. AbbVie's Venclexta plus Rituxan blew the doors off Rituxan plus chemo for a group of patients similar to those enrolled in the Unity study. TG Therapeutics: Tough ac... | Ublituximab and Gazyva both target CD20, and TG investors should be nervous about a treatment that AbbVie (NYSE: ABBV) already markets with great success. AbbVie's Venclexta plus Rituxan blew the doors off Rituxan plus chemo for a group of patients similar to those enrolled in the Unity study. Of course, some of these ... |
25,224 | 2018-12-11 00:00:00 UTC | Bristol-Myers to Study Opdivo in Combo With Vedanta's VE800 | ABBV | https://www.nasdaq.com/articles/bristol-myers-to-study-opdivo-in-combo-with-vedantas-ve800-2018-12-11 | null | null | Bristol-Myers Squibb CompanyBMY announced that it has signed a collaboration deal with Massachusetts-based, privately held Vedanta Biosciences, Inc. to evaluate its immuno-oncology drug, Opdivo, in combination with Vedanta's lead microbiome-based immuno-oncology candidate, VE800.
The collaboration study will evaluate B... | Notably, Bristol-Myers has inked collaboration deals with several research institutes, small and large biotech and pharma companies including Johns Hopkins University, Johnson & Johnson JNJ , AbbVie ABBV , Lilly LLY , Celgene, Nektar, Infinity Pharmaceuticals and Seattle Genetics for evaluating Opdivo in combination wi... | Notably, Bristol-Myers has inked collaboration deals with several research institutes, small and large biotech and pharma companies including Johns Hopkins University, Johnson & Johnson JNJ , AbbVie ABBV , Lilly LLY , Celgene, Nektar, Infinity Pharmaceuticals and Seattle Genetics for evaluating Opdivo in combination wi... | Notably, Bristol-Myers has inked collaboration deals with several research institutes, small and large biotech and pharma companies including Johns Hopkins University, Johnson & Johnson JNJ , AbbVie ABBV , Lilly LLY , Celgene, Nektar, Infinity Pharmaceuticals and Seattle Genetics for evaluating Opdivo in combination wi... | Notably, Bristol-Myers has inked collaboration deals with several research institutes, small and large biotech and pharma companies including Johns Hopkins University, Johnson & Johnson JNJ , AbbVie ABBV , Lilly LLY , Celgene, Nektar, Infinity Pharmaceuticals and Seattle Genetics for evaluating Opdivo in combination wi... |
25,225 | 2018-12-11 00:00:00 UTC | 4 “Powell-Proof” Stocks Set to Skyrocket in 2019 (and 1 to Sell Now) | ABBV | https://www.nasdaq.com/articles/4-powell-proof-stocks-set-skyrocket-2019-and-1-sell-now-2018-12-11 | null | null | By Brett Owens
If youaEURtmre confused about the direction of interest rates, donaEURtmt worryaEUR"Fed Chair Jerome Powell canaEURtmt figure it out either!
And today IaEURtmm going to show you 4 aEURoePowell-proofaEUR stocks set to explode in 2019aEUR"whether rates take off or freeze in place. First, back to Powell.
An... | By Brett Owens If youaEURtmre confused about the direction of interest rates, donaEURtmt worryaEUR"Fed Chair Jerome Powell canaEURtmt figure it out either! And today IaEURtmm going to show you 4 aEURoePowell-proofaEUR stocks set to explode in 2019aEUR"whether rates take off or freeze in place. An Epic Flip-Flop You may... | By Brett Owens If youaEURtmre confused about the direction of interest rates, donaEURtmt worryaEUR"Fed Chair Jerome Powell canaEURtmt figure it out either! HereaEURtms what followed: Loose Lips aEUR The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of ... | By Brett Owens If youaEURtmre confused about the direction of interest rates, donaEURtmt worryaEUR"Fed Chair Jerome Powell canaEURtmt figure it out either! An Epic Flip-Flop You may recall October 3, when the Fed chief, momentarily forgetting his words can tank the market, said, aEURoeWeaEURtmre a long way from neutral... | By Brett Owens If youaEURtmre confused about the direction of interest rates, donaEURtmt worryaEUR"Fed Chair Jerome Powell canaEURtmt figure it out either! And today IaEURtmm going to show you 4 aEURoePowell-proofaEUR stocks set to explode in 2019aEUR"whether rates take off or freeze in place. First, back to Powell. |
25,226 | 2018-12-11 00:00:00 UTC | How Worried Should You Be About AbbVie's $5.8 Billion Boondoggle? | ABBV | https://www.nasdaq.com/articles/how-worried-should-you-be-about-abbvies-58-billion-boondoggle-2018-12-11 | null | null | What's a 10-letter word that describes a waste of money that at one point had the appearance of adding value? Boondoggle. And the word could now apply to AbbVie 's (NYSE: ABBV) $5.8 billion acquisition of Stemcentrx.
When AbbVie announced the Stemcentrx deal in April 2016, the company expressed excitement and optimism ... | A big impact In 2016, AbbVie said that Rova-T "represents a multi-billion dollar peak revenue opportunity with expected commercialization in 2018." At the J.P. Morgan Healthcare Conference in January , AbbVie CEO Rick Gonzalez included Rova-T as one of several drugs that would help the company generate $35 billion in r... | The big investment in Stemcentrx appears to be a big waste of money after disappointing phase 2 results for Rova-T in March, followed by AbbVie halting a phase 3 study of the drug last week. AbbVie had targeted peak annual sales of around $5 billion for Rova-T. Now, though, the phase 3 clinical study of Rova-T as a sec... | The big investment in Stemcentrx appears to be a big waste of money after disappointing phase 2 results for Rova-T in March, followed by AbbVie halting a phase 3 study of the drug last week. AbbVie had targeted peak annual sales of around $5 billion for Rova-T. Now, though, the phase 3 clinical study of Rova-T as a sec... | AbbVie hopes to pick up a new indication for another already approved drug, Venclexta, in treating acute myeloid leukemia. And the word could now apply to AbbVie 's (NYSE: ABBV) $5.8 billion acquisition of Stemcentrx. When AbbVie announced the Stemcentrx deal in April 2016, the company expressed excitement and optimism... |
25,227 | 2018-12-11 00:00:00 UTC | Gilead Sciences (GILD) Appoints Daniel O'Day as New CEO | ABBV | https://www.nasdaq.com/articles/gilead-sciences-gild-appoints-daniel-oday-as-new-ceo-2018-12-11 | null | null | Gilead Sciences, Inc.GILD announced that its board of directors has appointed Daniel O'Day as the company's Chairman and Chief Executive Officer (CEO).
O'Day will take over the reins on Mar 1, 2019. Meanwhile, the board appointed Gregg Alton as interim CEO for the period of Jan 1 to Mar 1, 2019.
O'Day is the CEO of the... | However, the HCV franchise has been under pressure since the last three-four years due to competitive pressure from the likes of AbbbVie, Inc. ABBV . Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Sangamo Therapeutics, Inc. (SGMO): Free ... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Sangamo Therapeutics, Inc. (SGMO): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. However, the HCV franchis... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Sangamo Therapeutics, Inc. (SGMO): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. However, the HCV franchis... | However, the HCV franchise has been under pressure since the last three-four years due to competitive pressure from the likes of AbbbVie, Inc. ABBV . Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Sangamo Therapeutics, Inc. (SGMO): Free ... |
25,228 | 2018-12-10 00:00:00 UTC | Amgen (AMGN) Continues to Reward Shareholders, Ups Dividend | ABBV | https://www.nasdaq.com/articles/amgen-amgn-continues-to-reward-shareholders-ups-dividend-2018-12-10 | null | null | Amgen, Inc.AMGN has announced a 10% hike in its quarterly dividend. Quarterly dividend was increased from $1.32 per share to $1.45 per share. The first increased dividend will be paid on Mar 8, 2019 to shareholders of record as of Feb 15. The new quarterly dividend amounts to an annual dividend of $5.80 per share, whic... | Two of its biosimilars, Kanjinti (a biosimilar of Roche's RHHBY cancer drug Herceptin) and Amjevita (biosimilar of Abbvie's ABBV blockbuster RA drug, Humira) were launched in EU this year and can contribute to sales in the future quarters. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Nov... | Two of its biosimilars, Kanjinti (a biosimilar of Roche's RHHBY cancer drug Herceptin) and Amjevita (biosimilar of Abbvie's ABBV blockbuster RA drug, Humira) were launched in EU this year and can contribute to sales in the future quarters. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Nov... | Two of its biosimilars, Kanjinti (a biosimilar of Roche's RHHBY cancer drug Herceptin) and Amjevita (biosimilar of Abbvie's ABBV blockbuster RA drug, Humira) were launched in EU this year and can contribute to sales in the future quarters. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Nov... | Two of its biosimilars, Kanjinti (a biosimilar of Roche's RHHBY cancer drug Herceptin) and Amjevita (biosimilar of Abbvie's ABBV blockbuster RA drug, Humira) were launched in EU this year and can contribute to sales in the future quarters. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Nov... |
25,229 | 2018-12-10 00:00:00 UTC | AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-outpaces-stock-market-gains%3A-what-you-should-know-2018-12-10 | null | null | In the latest trading session, AbbVie (ABBV) closed at $87.59, marking a +0.72% move from the previous day. This change outpaced the S&P 500's 0.18% gain on the day. Meanwhile, the Dow gained 0.14%, and the Nasdaq, a tech-heavy index, added 0.74%.
Prior to today's trading, shares of the drugmaker had lost 0.88% over th... | In the latest trading session, AbbVie (ABBV) closed at $87.59, marking a +0.72% move from the previous day. Investors will be hoping for strength from ABBV as it approaches its next earnings release, which is expected to be January 25, 2019. On that day, ABBV is projected to report earnings of $1.92 per share, which wo... | In the latest trading session, AbbVie (ABBV) closed at $87.59, marking a +0.72% move from the previous day. Investors will be hoping for strength from ABBV as it approaches its next earnings release, which is expected to be January 25, 2019. On that day, ABBV is projected to report earnings of $1.92 per share, which wo... | ABBV's full-year Zacks Consensus Estimates are calling for earnings of $7.93 per share and revenue of $32.78 billion. In the latest trading session, AbbVie (ABBV) closed at $87.59, marking a +0.72% move from the previous day. Investors will be hoping for strength from ABBV as it approaches its next earnings release, wh... | On that day, ABBV is projected to report earnings of $1.92 per share, which would represent year-over-year growth of 29.73%. In terms of valuation, ABBV is currently trading at a Forward P/E ratio of 10.96. In the latest trading session, AbbVie (ABBV) closed at $87.59, marking a +0.72% move from the previous day. |
25,230 | 2018-12-09 00:00:00 UTC | Did Gilead Sciences Make an $11 Billion Blunder? | ABBV | https://www.nasdaq.com/articles/did-gilead-sciences-make-11-billion-blunder-2018-12-09 | null | null | I read an interesting article recently about Gilead Sciences (NASDAQ: GILD) . Bloomberg Opinion columnist Joe Nocera summarized Gilead's quest to market drugs that cure hepatitis C. The author did a great job explaining the unique challenges for Gilead and the entire biopharmaceutical industry in developing products th... | His main point is best summarized in this statement from the article: "But it turns out that Wall Street much prefers a drug like AbbVie 's (NYSE: ABBV) Humira, which treats -- but doesn't cure -- rheumatoid arthritis, Crohn's disease, and a variety of other illnesses." *Stock Advisor returns as of November 14, 2018 Ke... | His main point is best summarized in this statement from the article: "But it turns out that Wall Street much prefers a drug like AbbVie 's (NYSE: ABBV) Humira, which treats -- but doesn't cure -- rheumatoid arthritis, Crohn's disease, and a variety of other illnesses." *Stock Advisor returns as of November 14, 2018 Ke... | His main point is best summarized in this statement from the article: "But it turns out that Wall Street much prefers a drug like AbbVie 's (NYSE: ABBV) Humira, which treats -- but doesn't cure -- rheumatoid arthritis, Crohn's disease, and a variety of other illnesses." *Stock Advisor returns as of November 14, 2018 Ke... | His main point is best summarized in this statement from the article: "But it turns out that Wall Street much prefers a drug like AbbVie 's (NYSE: ABBV) Humira, which treats -- but doesn't cure -- rheumatoid arthritis, Crohn's disease, and a variety of other illnesses." *Stock Advisor returns as of November 14, 2018 Ke... |
25,231 | 2018-12-09 00:00:00 UTC | 3 Top Stocks to Buy in December | ABBV | https://www.nasdaq.com/articles/3-top-stocks-buy-december-2018-12-09 | null | null | Oh, the market is certainly frightful. But some stocks still look delightful. So if you want to make your money grow, you've got invest some dough.
My apologies to the composers of "Let It Snow!" However, my revised lyrics are right on target. Despite investors' fear and uncertainty about the stock market's current vol... | *Stock Advisor returns as of November 14, 2018 Keith Speights owns shares of AbbVie, MongoDB, and PayPal Holdings. Three that I especially like are AbbVie (NYSE: ABBV) , MongoDB (NASDAQ: MDB) , and PayPal Holdings (NASDAQ: PYPL) . AbbVie Let's start with AbbVie's mouthwatering dividend yield of 4.5%. | Three that I especially like are AbbVie (NYSE: ABBV) , MongoDB (NASDAQ: MDB) , and PayPal Holdings (NASDAQ: PYPL) . AbbVie Let's start with AbbVie's mouthwatering dividend yield of 4.5%. But I think AbbVie should deliver significant gains over the next few years. | *Stock Advisor returns as of November 14, 2018 Keith Speights owns shares of AbbVie, MongoDB, and PayPal Holdings. Three that I especially like are AbbVie (NYSE: ABBV) , MongoDB (NASDAQ: MDB) , and PayPal Holdings (NASDAQ: PYPL) . AbbVie Let's start with AbbVie's mouthwatering dividend yield of 4.5%. | Three that I especially like are AbbVie (NYSE: ABBV) , MongoDB (NASDAQ: MDB) , and PayPal Holdings (NASDAQ: PYPL) . AbbVie Let's start with AbbVie's mouthwatering dividend yield of 4.5%. But I think AbbVie should deliver significant gains over the next few years. |
25,232 | 2018-12-09 00:00:00 UTC | Here's Why AbbVie Stock Surged 21.1% in November | ABBV | https://www.nasdaq.com/articles/heres-why-abbvie-stock-surged-211-november-2018-12-09 | null | null | What happened
Shares of AbbVie (NYSE: ABBV) , the pharmaceutical company behind all those Humira advertisements, soared 21.1% in November, according to data from S&P Global Market Intelligence . The stock began November near a 52-week low, but impressive results from the company's blood cancer studies helped turn the s... | What happened Shares of AbbVie (NYSE: ABBV) , the pharmaceutical company behind all those Humira advertisements, soared 21.1% in November, according to data from S&P Global Market Intelligence . So what October ended on such a low note that a solid third-quarter report combined with positive news for the company's bloo... | So what October ended on such a low note that a solid third-quarter report combined with positive news for the company's blood cancer treatments were enough to help AbbVie stock recover. AbbVie's share of Imbruvica sales reached $2.6 billion during the first nine months of 2018 and will probably pass $5 billion in 2019... | So what October ended on such a low note that a solid third-quarter report combined with positive news for the company's blood cancer treatments were enough to help AbbVie stock recover. AbbVie's increased its dividend more than once in the past year, and it looks as if rising sales of blood cancer treatments could mak... | AbbVie's increased its dividend more than once in the past year, and it looks as if rising sales of blood cancer treatments could make it possible to steadily raise the payout despite the impending loss of Humira sales in the years ahead. What happened Shares of AbbVie (NYSE: ABBV) , the pharmaceutical company behind a... |
25,233 | 2018-12-09 00:00:00 UTC | Here's Why BeiGene Stock Rose 21.7% in November | ABBV | https://www.nasdaq.com/articles/heres-why-beigene-stock-rose-217-november-2018-12-09 | null | null | What happened
Shares of Beigene (NASDAQ: BGNE) , an oncology-focused biotech out of China, rose 21.7% in November, according to data from S&P Global Market Intelligence . Investors looking forward to sales of two drugs under review in China helped the stock regain some of October's losses.
So what
Beigene markets Celge... | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) share rights to Imbruvica, and combined sales of the drug will probably pass $10 billion by 2020. So what Beigene markets Celgene 's (NASDAQ: CELG) therapies in China, including Revlimid, which is on pace to generate $9.7 billion in total sales this year. The China ... | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) share rights to Imbruvica, and combined sales of the drug will probably pass $10 billion by 2020. Next year, we'll also find out if zanubrutinib beat Imbruvica during an ongoing head-to-head study with newly diagnosed leukemia patients. *Stock Advisor returns as of ... | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) share rights to Imbruvica, and combined sales of the drug will probably pass $10 billion by 2020. So what Beigene markets Celgene 's (NASDAQ: CELG) therapies in China, including Revlimid, which is on pace to generate $9.7 billion in total sales this year. If Beigene... | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) share rights to Imbruvica, and combined sales of the drug will probably pass $10 billion by 2020. Last month, investors were also encouraged by priority reviews that the CFDA granted for two new drug applications that Beigene submitted earlier this year. If Beigene'... |
25,234 | 2018-12-06 00:00:00 UTC | AbbVie Halts Rova-T Phase III Second-Line Lung Cancer Study | ABBV | https://www.nasdaq.com/articles/abbvie-halts-rova-t-phase-iii-second-line-lung-cancer-study-2018-12-06 | null | null | AbbVie, Inc.ABBV announced that it has stopped enrollments in a pivotal phase III study -TAHOE - evaluating its cancer candidate rovalpituzumab tesirine or Rova-T in second-line small cell lung cancer (SCLC).
AbbVie said that the Independent Data Monitoring Committee (IDMC), responsible for ongoing review of data, reco... | Also, in July, AbbVie filed U.S. regulatory application for Venclexta in first-line AML while data from the phase III program in multiple myeloma is expected in first half of 2019. AbbVie, Inc.ABBV announced that it has stopped enrollments in a pivotal phase III study -TAHOE - evaluating its cancer candidate rovalpituz... | Also, in July, AbbVie filed U.S. regulatory application for Venclexta in first-line AML while data from the phase III program in multiple myeloma is expected in first half of 2019. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Johnson & ... | AbbVie, Inc.ABBV announced that it has stopped enrollments in a pivotal phase III study -TAHOE - evaluating its cancer candidate rovalpituzumab tesirine or Rova-T in second-line small cell lung cancer (SCLC). AbbVie is also studying another key cancer drug, Venclyxto/Venclexta in label expansion studies to address the ... | AbbVie clarified that IDMC's recommendation is only for the TAHOE study and does not apply to other studies on Rova-T. AbbVie, Inc.ABBV announced that it has stopped enrollments in a pivotal phase III study -TAHOE - evaluating its cancer candidate rovalpituzumab tesirine or Rova-T in second-line small cell lung cancer ... |
25,235 | 2018-12-05 00:00:00 UTC | 7 Dividend Aristocrats to Buy for 2019 | ABBV | https://www.nasdaq.com/articles/7-dividend-aristocrats-buy-2019-2018-12-05 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
We're quickly approaching the end of 2018. That's got most investors reminiscing about the year that was in the markets while also pondering which stocks to buy in the year ahead.
I know I sure am.
This year volatility returned to the markets making the ave... | Stocks to Buy for 2019: AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) Current Yield: 4.6% The great thing about all 53 of the Dividend Aristocrats is that you know they're consistently going to pay a dividend to keep that title - even when their businesses aren't performing at 100%. AbbVie (NYSE: ABBV ) h... | Stocks to Buy for 2019: AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) Current Yield: 4.6% The great thing about all 53 of the Dividend Aristocrats is that you know they're consistently going to pay a dividend to keep that title - even when their businesses aren't performing at 100%. AbbVie (NYSE: ABBV ) h... | Regarding free cash flow, AbbVie's generated $9.5 billion through the first three quarters of the year, $2.5 billion higher than in the same period last year. Stocks to Buy for 2019: AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) Current Yield: 4.6% The great thing about all 53 of the Dividend Aristocrats ... | Stocks to Buy for 2019: AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) Current Yield: 4.6% The great thing about all 53 of the Dividend Aristocrats is that you know they're consistently going to pay a dividend to keep that title - even when their businesses aren't performing at 100%. AbbVie (NYSE: ABBV ) h... |
25,236 | 2018-12-05 00:00:00 UTC | J&J's Blood Cancer Drugs Succeed in Label Expansion Studies | ABBV | https://www.nasdaq.com/articles/jjs-blood-cancer-drugs-succeed-in-label-expansion-studies-2018-12-05 | null | null | Johnson & JohnsonJNJ presented positive data from late-stage label expansion studies evaluating its blood cancer drugs, Imbruvica and Darzalex, in previously untreated patients at the annual meeting of the American Society of Hematology (ASH) held in San Diego, CA.
New findings from a phase III study showed that its ke... | J&J markets Imbruvica in partnership with AbbVie ABBV . Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report To read this article on Zac... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. J&J markets Imbruvica in partnership ... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. J&J markets Imbruvica in partnership ... | J&J markets Imbruvica in partnership with AbbVie ABBV . Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report To read this article on Zac... |
25,237 | 2018-12-05 00:00:00 UTC | Gilead's (GILD) Harvoni and Descovy Get Approval in China | ABBV | https://www.nasdaq.com/articles/gileads-gild-harvoni-and-descovy-get-approval-in-china-2018-12-05 | null | null | Gilead Sciences, Inc . GILD announced that the National Medical Products Administration (NMPA) has approved its hepatitis C virus (HCV) drug, Harvoni, in China.
The drug has been approved for the treatment of HCV infection genotype 1-6 infection in adults and adolescents aged 12-18 years.
The approval should boost sale... | The approval should boost sales of the dwindling HCV franchise due to competitive pressure from the likes of AbbVie ABBV . Click to get this free report GlaxoSmithKline plc (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Sangamo T... | Click to get this free report GlaxoSmithKline plc (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Sangamo Therapeutics, Inc. (SGMO): Free Stock Analysis Report To read this article on Zacks.com click here. The approval should boos... | Click to get this free report GlaxoSmithKline plc (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Sangamo Therapeutics, Inc. (SGMO): Free Stock Analysis Report To read this article on Zacks.com click here. The approval should boos... | The approval should boost sales of the dwindling HCV franchise due to competitive pressure from the likes of AbbVie ABBV . Click to get this free report GlaxoSmithKline plc (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Sangamo T... |
25,238 | 2018-12-04 00:00:00 UTC | Wall Street Is Souring on These 7 Stocks to Sell | ABBV | https://www.nasdaq.com/articles/wall-street-souring-these-7-stocks-sell-2018-12-04 | null | null | There's a lot of talk about Wall Street's top-rated stocks. As 2018 ends and 2019 nears, everyone - including us - is talking about our favorite stock picks for 2019 , or even the next decade.
But not every stock is a well-loved lunker.
There are numerous stocks with bearish, or at least increasingly bearish, Wall Stre... | SEE ALSO: 10 Stocks Warren Buffett Is Buying (And 6 He's Selling) Market value: $138.2 billion TipRanks consensus price target: $98.10 (5% upside potential) TipRanks consensus rating: Hold AbbVie ( ABBV , $93.66) - a spinoff of Abbott Laboratories ( ABT ) - is the pharmaceutical company known for Humira, one of the gre... | SEE ALSO: 10 Stocks Warren Buffett Is Buying (And 6 He's Selling) Market value: $138.2 billion TipRanks consensus price target: $98.10 (5% upside potential) TipRanks consensus rating: Hold AbbVie ( ABBV , $93.66) - a spinoff of Abbott Laboratories ( ABT ) - is the pharmaceutical company known for Humira, one of the gre... | SEE ALSO: 10 Stocks Warren Buffett Is Buying (And 6 He's Selling) Market value: $138.2 billion TipRanks consensus price target: $98.10 (5% upside potential) TipRanks consensus rating: Hold AbbVie ( ABBV , $93.66) - a spinoff of Abbott Laboratories ( ABT ) - is the pharmaceutical company known for Humira, one of the gre... | SEE ALSO: 10 Stocks Warren Buffett Is Buying (And 6 He's Selling) Market value: $138.2 billion TipRanks consensus price target: $98.10 (5% upside potential) TipRanks consensus rating: Hold AbbVie ( ABBV , $93.66) - a spinoff of Abbott Laboratories ( ABT ) - is the pharmaceutical company known for Humira, one of the gre... |
25,239 | 2018-12-04 00:00:00 UTC | Roche Announces Positive Data on Venclexta/Venclyxto at ASH | ABBV | https://www.nasdaq.com/articles/roche-announces-positive-data-on-venclexta-venclyxto-at-ash-2018-12-04 | null | null | RocheHolding AGRHHBY announced new data from the phase III MURANO study on Venclexta/Venclyxto (venetoclax) in patients with previously treated chronic lymphocytic leukemia (CLL) at the American Society of Hematology (ASH) 2018 Annual Meeting.
Share price of the company has increased 6.2% year to date compared with the... | We remind investors that, Venclexta/Venclyxto is being developed by AbbVie ABBV and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the United States, and commercialized by AbbVie outside of the United States. Click to get this free report Bristol-Myers Squibb Company (BMY):... | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. We remind ... | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. We remind ... | We remind investors that, Venclexta/Venclyxto is being developed by AbbVie ABBV and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the United States, and commercialized by AbbVie outside of the United States. Click to get this free report Bristol-Myers Squibb Company (BMY):... |
25,240 | 2018-12-03 00:00:00 UTC | AbbVie Settles With Pfizer for Humira Biosimilar in U.S. | ABBV | https://www.nasdaq.com/articles/abbvie-settles-with-pfizer-for-humira-biosimilar-in-u.s.-2018-12-03 | null | null | AbbVie, Inc.ABBV signed a non-exclusive licensing deal with Pfizer PFE regarding the latter's proposed biosimilar version of its blockbuster rheumatoid arthritis drug, Humira. Per the deal, Pfizer will have a non-exclusive license to launch its biosimilar Humira in the United States on Nov 20, 2023. In the EU, Pfizer c... | AbbVie, Inc.ABBV signed a non-exclusive licensing deal with Pfizer PFE regarding the latter's proposed biosimilar version of its blockbuster rheumatoid arthritis drug, Humira. The settlements give AbbVie more time to strengthen its pipeline with products that are capable of making up for the expected sales decline when... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie, Inc.ABBV signed a non-exclusive licensing deal with ... | AbbVie made it clear that Pfizer's U.S. license will not be accelerated by biosimilar launches by other companies, which have similar licensing deals AbbVie. The settlements give AbbVie more time to strengthen its pipeline with products that are capable of making up for the expected sales decline when Humira biosimilar... | The settlements give AbbVie more time to strengthen its pipeline with products that are capable of making up for the expected sales decline when Humira biosimilars are launched. AbbVie, Inc.ABBV signed a non-exclusive licensing deal with Pfizer PFE regarding the latter's proposed biosimilar version of its blockbuster r... |
25,241 | 2018-12-03 00:00:00 UTC | XLV, PFE, MRK, ABBV: ETF Inflow Alert | ABBV | https://www.nasdaq.com/articles/xlv-pfe-mrk-abbv-etf-inflow-alert-2018-12-03 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $417.9 million dollar inflow -- that's a 2.1% increase week over week in outstanding units (from 205,... | Among the largest underlying components of XLV, in trading today Pfizer Inc (Symbol: PFE) is off about 0.3%, Merck & Co Inc (Symbol: MRK) is down about 0.8%, and AbbVie Inc (Symbol: ABBV) is up by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , ... | Among the largest underlying components of XLV, in trading today Pfizer Inc (Symbol: PFE) is off about 0.3%, Merck & Co Inc (Symbol: MRK) is down about 0.8%, and AbbVie Inc (Symbol: ABBV) is up by about 0.4%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price perform... | Among the largest underlying components of XLV, in trading today Pfizer Inc (Symbol: PFE) is off about 0.3%, Merck & Co Inc (Symbol: MRK) is down about 0.8%, and AbbVie Inc (Symbol: ABBV) is up by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , ... | Among the largest underlying components of XLV, in trading today Pfizer Inc (Symbol: PFE) is off about 0.3%, Merck & Co Inc (Symbol: MRK) is down about 0.8%, and AbbVie Inc (Symbol: ABBV) is up by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , ... |
25,242 | 2018-12-03 00:00:00 UTC | AbbVie Stock Could Become a New Happy Pill for Investors | ABBV | https://www.nasdaq.com/articles/abbvie-stock-could-become-new-happy-pill-investors-2018-12-03 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
While AbbVie (NYSE: ABBV ) has shown strong profit growth over the last year, ABBV stock has sold off recently over worries about Humira patent expirations in some parts of the world.
Although the concerns may be overblown, losing any patent protection on t... | What gives investors confidence in the shares, though, is a promising drug pipeline should keep AbbVie stock on a growth trajectory even as Humira fades as a significant revenue contributor. Given company growth prospects and the expectations for increases that come with its aristocrat status, income investors will str... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips While AbbVie (NYSE: ABBV ) has shown strong profit growth over the last year, ABBV stock has sold off recently over worries about Humira patent expirations in some parts of the world. Bottom Line on AbbVie Stock As Humira begins a slow fade from driving Abb... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips While AbbVie (NYSE: ABBV ) has shown strong profit growth over the last year, ABBV stock has sold off recently over worries about Humira patent expirations in some parts of the world. Bottom Line on AbbVie Stock As Humira begins a slow fade from driving Abb... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips While AbbVie (NYSE: ABBV ) has shown strong profit growth over the last year, ABBV stock has sold off recently over worries about Humira patent expirations in some parts of the world. ABBV stock has sold off as investors wonder where the company will go nex... |
25,243 | 2018-12-02 00:00:00 UTC | Why Is AbbVie (ABBV) Up 17.5% Since Last Earnings Report? | ABBV | https://www.nasdaq.com/articles/why-is-abbvie-abbv-up-17.5-since-last-earnings-report-2018-12-02 | null | null | A month has gone by since the last earnings report for AbbVie (ABBV). Shares have added about 17.5% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is AbbVie due for a pullback? Before we dive into how investors and analysts have reacted... | The first increased dividend will be paid on Feb 15, 2019 to shareholders of record as of Jan 15, 2019 2018 Outlook AbbVie raised its adjusted EPS guidance to the range of $7.90-$7.92 for 2018 from $7.76-$7.86 predicted earlier. Preliminary Outlook for 2019 AbbVie said it is confident of delivering double-digit earning... | AbbVie Q3 Earnings Beat Estimates, 2018 EPS View Up Third-quarter 2018 earnings of $2.14 per share beat the Zacks Consensus Estimate of $2.01. A month has gone by since the last earnings report for AbbVie (ABBV). Will the recent positive trend continue leading up to its next earnings release, or is AbbVie due for a pul... | A month has gone by since the last earnings report for AbbVie (ABBV). Will the recent positive trend continue leading up to its next earnings release, or is AbbVie due for a pullback? AbbVie Q3 Earnings Beat Estimates, 2018 EPS View Up Third-quarter 2018 earnings of $2.14 per share beat the Zacks Consensus Estimate of ... | AbbVie Q3 Earnings Beat Estimates, 2018 EPS View Up Third-quarter 2018 earnings of $2.14 per share beat the Zacks Consensus Estimate of $2.01. A month has gone by since the last earnings report for AbbVie (ABBV). Will the recent positive trend continue leading up to its next earnings release, or is AbbVie due for a pul... |
25,244 | 2018-11-30 00:00:00 UTC | The New Amazon Blockchain Products Could Be Huge for AMZN | ABBV | https://www.nasdaq.com/articles/new-amazon-blockchain-products-could-be-huge-amzn-2018-11-30 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
There's no doubt that Amazon (NASDAQ: AMZN ) is a destructive force when it enters a new sector. After all, "your margin is my opportunity." Just the thought of AMZN changing healthcare hit many of the sector's stocks incredibly hard. So, when Amazon sets i... | Names like AbbVie (NASDAQ: ABBV ), Netflix (NASDAQ: NFLX ) and Airbnb are just some of the firms using AWS services. Disclosure: At the time of writing, Aaron Levitt was long ABBV stock. Amazon Gets Blockchain Fever You can debate all day on whether digital currencies like bitcoin, ethereum or dogecoin have any actual ... | Names like AbbVie (NASDAQ: ABBV ), Netflix (NASDAQ: NFLX ) and Airbnb are just some of the firms using AWS services. Disclosure: At the time of writing, Aaron Levitt was long ABBV stock. To that end, AMZN just announced that it will offer two Amazon Blockchain services through AWS: Amazon Quantum Ledger Database and Am... | Names like AbbVie (NASDAQ: ABBV ), Netflix (NASDAQ: NFLX ) and Airbnb are just some of the firms using AWS services. Disclosure: At the time of writing, Aaron Levitt was long ABBV stock. To that end, AMZN just announced that it will offer two Amazon Blockchain services through AWS: Amazon Quantum Ledger Database and Am... | Names like AbbVie (NASDAQ: ABBV ), Netflix (NASDAQ: NFLX ) and Airbnb are just some of the firms using AWS services. Disclosure: At the time of writing, Aaron Levitt was long ABBV stock. And this time, AMZN is getting ready to change a potentially game-changing sector. |
25,245 | 2018-11-30 00:00:00 UTC | Key Pharma Players With HIV Focus Ahead of World Aids Day | ABBV | https://www.nasdaq.com/articles/key-pharma-players-hiv-focus-ahead-world-aids-day-2018-11-30 | null | null | Acquired Immuno Deficiency Syndrome, popularly known as AIDS, is a pandemic caused due to the infection of human immunodeficiency virus ("HIV"). The virus weakens the immune system by destroying cells that fight diseases and infections, eventually leading to AIDS. Medicines for the treatment of HIV are called antiretro... | Other Drugs Some other popular marketed HIV drugs are AbbVie's ABBV , Kaletra and Merck's MRK Isentress. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free St... | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zack... | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zack... | Other Drugs Some other popular marketed HIV drugs are AbbVie's ABBV , Kaletra and Merck's MRK Isentress. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free St... |
25,246 | 2018-11-30 00:00:00 UTC | 3 Beaten-Down Biotech Stocks to Buy Before the End of 2018 | ABBV | https://www.nasdaq.com/articles/3-beaten-down-biotech-stocks-buy-end-2018-2018-11-30 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Biotech stocks, like the rest of the broader market, have been under heavy pressure in late 2018. The iShares Nasdaq Biotechnology ETF (NASDAQ: IBB ), which includes several of the largest biotechnology stocks, and the SPDR S&P Biotech ETF (NYSEARCA: XBI ),... | Furthermore, AbbVie's healthy dividend yield of 5% is likely to provide strong support for the ABBV stock price in the weeks and months ahead. Although many of these biotech stocks, including AbbVie (NYSE: ABBV ), Celgene (NASDAQ: CELG ) and Mylan (NASDAQ: MYL ), are much cheaper than they were at the start of Septembe... | Although many of these biotech stocks, including AbbVie (NYSE: ABBV ), Celgene (NASDAQ: CELG ) and Mylan (NASDAQ: MYL ), are much cheaper than they were at the start of September, investors should not expect the choppiness in individual share prices to be over yet. The Bottom Line on These Three Biotechnology Stocks So... | The Bottom Line on These Three Biotechnology Stocks Source: Shutterstock All three biotech stocks, ABBV, CELG and MYL stock, have strong fundamental growth prospects in the long-run, despite having come off significantly from their recent highs. If I had to rank them, I would start the buying with ABBV stock, followed ... | Although many of these biotech stocks, including AbbVie (NYSE: ABBV ), Celgene (NASDAQ: CELG ) and Mylan (NASDAQ: MYL ), are much cheaper than they were at the start of September, investors should not expect the choppiness in individual share prices to be over yet. Furthermore, AbbVie's healthy dividend yield of 5% is ... |
25,247 | 2018-11-29 00:00:00 UTC | Global Dividends Get Richer | ABBV | https://www.nasdaq.com/articles/global-dividends-get-richer-2018-11-29 | null | null | Photograph by Adolfo Felix
Global dividends had a strong third quarter, helped by record quarterly payments in the U.S., Canada, Taiwan, and India.
In all, dividends tracked by the Janus Henderson Global Dividend index totaled $354.2 billion, up 5.1% from $337 billion in 2017's third quarter.
In local currency and excl... | Pharmaceutical giant AbbVie (ABBV), whose biggest-selling drug is Humira, paid a dividend of 96 cents a share in the third quarter, up from 64 cents a year earlier. In its release of the latest survey results, it notes that "the pace of dividend increases could slow as companies come to terms with what is likely in the... | Pharmaceutical giant AbbVie (ABBV), whose biggest-selling drug is Humira, paid a dividend of 96 cents a share in the third quarter, up from 64 cents a year earlier. In all, dividends tracked by the Janus Henderson Global Dividend index totaled $354.2 billion, up 5.1% from $337 billion in 2017's third quarter. In the U.... | Pharmaceutical giant AbbVie (ABBV), whose biggest-selling drug is Humira, paid a dividend of 96 cents a share in the third quarter, up from 64 cents a year earlier. In all, dividends tracked by the Janus Henderson Global Dividend index totaled $354.2 billion, up 5.1% from $337 billion in 2017's third quarter. In local ... | Pharmaceutical giant AbbVie (ABBV), whose biggest-selling drug is Humira, paid a dividend of 96 cents a share in the third quarter, up from 64 cents a year earlier. In local currency and excluding special dividends and other factors, dividends increased 9.2% in the third quarter. There was also a big uptick in dividend... |
25,248 | 2018-11-29 00:00:00 UTC | How Google Is Helping Make Advances In Medical Technology | ABBV | https://www.nasdaq.com/articles/how-google-helping-make-advances-medical-technology-2018-11-29 | null | null | daizuoxin for Getty images
Over the years, medical science has seen tremendous advancements. However, there is always scope for improvement and this time around, doctors and nurses have access to devices, apps and platforms powered with advanced technologies such as Artificial Intelligence, Cloud, Machine Learning—to e... | Back in 2014, Calico (earlier known as Google Life Sciences) and AbbVie (ABBV) joined hands to focus on new therapies for patients with age-related diseases such as neuro-degeneration and cancer. However, there is always scope for improvement and this time around, doctors and nurses have access to devices, apps and pla... | Back in 2014, Calico (earlier known as Google Life Sciences) and AbbVie (ABBV) joined hands to focus on new therapies for patients with age-related diseases such as neuro-degeneration and cancer. Deloitte estimates that the global health care spending is projected to increase at an annual rate of 4.1% in 2017-2021, up ... | Back in 2014, Calico (earlier known as Google Life Sciences) and AbbVie (ABBV) joined hands to focus on new therapies for patients with age-related diseases such as neuro-degeneration and cancer. While Google’s Apigee Health APIx makes it easy for developers and healthcare enterprises to build new FHIR (Fast Healthcare... | Back in 2014, Calico (earlier known as Google Life Sciences) and AbbVie (ABBV) joined hands to focus on new therapies for patients with age-related diseases such as neuro-degeneration and cancer. Here are some of the projects and initiatives within the healthcare space by Alphabet and its subsidiaries. “Healthcare is i... |
25,249 | 2018-11-28 00:00:00 UTC | AbbVie (ABBV) Gains But Lags Market: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-gains-but-lags-market%3A-what-you-should-know-2018-11-28 | null | null | AbbVie (ABBV) closed the most recent trading day at $88.93, moving +1.43% from the previous trading session. The stock lagged the S&P 500's daily gain of 2.3%. Meanwhile, the Dow gained 2.5%, and the Nasdaq, a tech-heavy index, added 2.95%.
Coming into today, shares of the drugmaker had gained 7.46% in the past month. ... | ABBV's full-year Zacks Consensus Estimates are calling for earnings of $7.93 per share and revenue of $32.78 billion. AbbVie (ABBV) closed the most recent trading day at $88.93, moving +1.43% from the previous trading session. ABBV will be looking to display strength as it nears its next earnings release, which is expe... | AbbVie (ABBV) closed the most recent trading day at $88.93, moving +1.43% from the previous trading session. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. ABBV will be looking to display strength as it nears its next earnings release, which is... | ABBV's full-year Zacks Consensus Estimates are calling for earnings of $7.93 per share and revenue of $32.78 billion. AbbVie (ABBV) closed the most recent trading day at $88.93, moving +1.43% from the previous trading session. ABBV will be looking to display strength as it nears its next earnings release, which is expe... | In that report, analysts expect ABBV to post earnings of $1.92 per share. AbbVie (ABBV) closed the most recent trading day at $88.93, moving +1.43% from the previous trading session. ABBV will be looking to display strength as it nears its next earnings release, which is expected to be January 25, 2019. |
25,250 | 2018-11-27 00:00:00 UTC | 5 Biotech Stocks to Scoop Up for Big Dividends | ABBV | https://www.nasdaq.com/articles/5-biotech-stocks-scoop-big-dividends-2018-11-27 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
When it comes to biotech stocks, the perception is that the sector is a gamble. Many investors believe that most biotech stocks are clinical-stage lotto tickets that will only succeed on a wish and a prayer. And that is true to a point. There are plenty of ... | With a hefty cash balance and continued clinical wins, ABBV offers a rare opportunity among biotechs: a high yield that is actually safe. AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) Dividend Yield : 5% A big-time approval can do wonders for your future. Just ask AbbVie Inc. (NASDAQ: ABBV ). | AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) Dividend Yield : 5% A big-time approval can do wonders for your future. Just ask AbbVie Inc. (NASDAQ: ABBV ). The story at ABBV has long been Humira. | At the time of writing, Aaron Levitt held a long position in AGN, AMGN, ABBV and GLPG More From InvestorPlace 2 Toxic Pot Stocks You Should Avoid 10 Cheap Stocks You Won't Regret Buying 7 Best Stock Charts Going Into 2019 5 Best ETFs for Slow and Steady Growth Compare Brokers The post 5 Biotech Stocks to Scoop Up for B... | Just ask AbbVie Inc. (NASDAQ: ABBV ). AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) Dividend Yield : 5% A big-time approval can do wonders for your future. The story at ABBV has long been Humira. |
25,251 | 2018-11-26 00:00:00 UTC | 2 Dividend Stocks You'll Wish You'd Bought 32 Years From Now | ABBV | https://www.nasdaq.com/articles/2-dividend-stocks-youll-wish-youd-bought-32-years-now-2018-11-26 | null | null | The baby boomer generation was much larger than those before or after, and by 2050, all 77 million members will have celebrated their 85th birthdays. They're going to need a lot of healthcare, and it looks as if there'll be plenty of working-age millennials to pay the bills.
American adults under 35 might not fill ever... | Global Humira sales have probably hit a high-water mark now that the main patents protecting its market exclusivity in the U.S. and EU have expired, but AbbVie's blood cancer program is just getting started. AbbVie's going to be on the opposite end of the excitement spectrum in the decades ahead, but investors still ho... | AbbVie: The right products for tomorrow Older adults are generally more susceptible to inflammatory conditions and cancer, which are two areas where AbbVie excels and is positioned to continue leading in the years ahead. Global Humira sales have probably hit a high-water mark now that the main patents protecting its ma... | AbbVie: The right products for tomorrow Older adults are generally more susceptible to inflammatory conditions and cancer, which are two areas where AbbVie excels and is positioned to continue leading in the years ahead. Global Humira sales have probably hit a high-water mark now that the main patents protecting its ma... | AbbVie: The right products for tomorrow Older adults are generally more susceptible to inflammatory conditions and cancer, which are two areas where AbbVie excels and is positioned to continue leading in the years ahead. Global Humira sales have probably hit a high-water mark now that the main patents protecting its ma... |
25,252 | 2018-11-26 00:00:00 UTC | The Zacks Analyst Blog Highlights: Pfizer, AbbVie, J&J, Glaxo and AstraZeneca | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-pfizer-abbvie-jj-glaxo-and-astrazeneca-2018-11-26 | null | null | For Immediate Release
Chicago, IL -November 26, 2018 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: PfizerPFE , AbbVieABBV , J... | Stocks recently featured in the blog include: PfizerPFE , AbbVieABBV , J&JJNJ , GlaxoGSK and AstraZenecaAZN . Here are highlights from Friday's Analyst Blog: Pharma Stock Roundup: PFE, ABBV & More This week, the FDA granted approval to Pfizer's Daurismo, the drug giant's fourth new cancer drug in less than three months... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report To read this article on Zacks.com click h... | AbbVie/Roche Get FDA Nod for Venclexta in First-Line AML : FDA also granted accelerated approval to AbbVie and partner Roche's supplemental new drug application (sNDA) looking for a label expansion of Venclexta (venetoclax) for the first-line treatment of acute myeloid leukemia (AML), one of the most aggressive blood c... | AbbVie/Roche Get FDA Nod for Venclexta in First-Line AML : FDA also granted accelerated approval to AbbVie and partner Roche's supplemental new drug application (sNDA) looking for a label expansion of Venclexta (venetoclax) for the first-line treatment of acute myeloid leukemia (AML), one of the most aggressive blood c... |
25,253 | 2018-11-26 00:00:00 UTC | Gilead's HIV Franchise, CAR T Therapy Likely to Propel Growth | ABBV | https://www.nasdaq.com/articles/gileads-hiv-franchise-car-t-therapy-likely-to-propel-growth-2018-11-26 | null | null | Shares of biotech bigwig Gilead Sciences, Inc . GILD have inched up 0.4% in the past six months, against the industry 's 10.3% decline.
While the legacy HCV business has declined significantly of late due to competitive pressure from the likes of AbbVie ABBV , among others, the company's HIV business has maintained mom... | While the legacy HCV business has declined significantly of late due to competitive pressure from the likes of AbbVie ABBV , among others, the company's HIV business has maintained momentum. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Repor... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Sangamo Therapeutics, Inc. (SGMO): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. While the legacy HCV bus... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Sangamo Therapeutics, Inc. (SGMO): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. While the legacy HCV bus... | While the legacy HCV business has declined significantly of late due to competitive pressure from the likes of AbbVie ABBV , among others, the company's HIV business has maintained momentum. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Repor... |
25,254 | 2018-11-25 00:00:00 UTC | 2 Cheap Dividend Stocks You Can Buy Right Now | ABBV | https://www.nasdaq.com/articles/2-cheap-dividend-stocks-you-can-buy-right-now-2018-11-25 | null | null | Patient investors who let cash accumulate during the bull market of early 2018 have more than leftover turkey to be thankful for at the moment. After tumbling along with much of the broad market, shares of AbbVie (NYSE: ABBV) and Physicians Realty Trust (NYSE: DOC) offer healthy dividends at attractive yields.
Above-av... | Despite being a Dividend Aristocrat with screaming-fast earnings growth, AbbVie stock has fallen about 30% from a peak reached in January, when it assured investors that Humira sales would continue rising for at least a few more years despite the expiration of its main U.S. patent. Humira biosimilars launched in the EU... | After tumbling along with much of the broad market, shares of AbbVie (NYSE: ABBV) and Physicians Realty Trust (NYSE: DOC) offer healthy dividends at attractive yields. AbbVie: A Dividend Aristocrat offering 5% When AbbVie reported third-quarter earnings recently, management raised its adjusted earnings-per-share outloo... | AbbVie: A Dividend Aristocrat offering 5% When AbbVie reported third-quarter earnings recently, management raised its adjusted earnings-per-share outlook to a level that is 41% higher than last year. Despite being a Dividend Aristocrat with screaming-fast earnings growth, AbbVie stock has fallen about 30% from a peak r... | Despite being a Dividend Aristocrat with screaming-fast earnings growth, AbbVie stock has fallen about 30% from a peak reached in January, when it assured investors that Humira sales would continue rising for at least a few more years despite the expiration of its main U.S. patent. After tumbling along with much of the... |
25,255 | 2018-11-23 00:00:00 UTC | Pharma Stock Roundup: Cancer Approvals for PFE & ABBV, CHMP Nod for Several Drugs | ABBV | https://www.nasdaq.com/articles/pharma-stock-roundup%3A-cancer-approvals-for-pfe-abbv-chmp-nod-for-several-drugs-2018-11-23 | null | null | This week, the FDA granted approval to Pfizer's PFE Daurismo, the drug giant's fourth new cancer drug in less than three months. It also approved the label expansion of AbbVie ABBV /Roche's drug Venclexta. Both the drugs gained approval for the treatment of acute myeloid leukemia (AML), a rare blood cancer in newly dia... | It also approved the label expansion of AbbVie ABBV /Roche's drug Venclexta. AbbVie/Roche Get FDA Nod for Venclexta in First-Line AML : FDA also granted accelerated approval to AbbVie and partner Roche's supplemental new drug application (sNDA) looking for a label expansion of Venclexta (venetoclax) for the first-line ... | Click to get this free report Sanofi (SNY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report GlaxoSmi... | Click to get this free report Sanofi (SNY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report GlaxoSmi... | AbbVie/Roche Get FDA Nod for Venclexta in First-Line AML : FDA also granted accelerated approval to AbbVie and partner Roche's supplemental new drug application (sNDA) looking for a label expansion of Venclexta (venetoclax) for the first-line treatment of acute myeloid leukemia (AML), one of the most aggressive blood c... |
25,256 | 2018-11-21 00:00:00 UTC | AbbVie (ABBV) Shares Cross 5% Yield Mark | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-shares-cross-5-yield-mark-2018-11-21 | null | null | Looking at the universe of stocks we cover at Dividend Channel , in trading on Wednesday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 5% mark based on its quarterly dividend (annualized to $4.28), with the stock changing hands as low as $85.37 on the day. Dividends are particularly important for investo... | Looking at the universe of stocks we cover at Dividend Channel , in trading on Wednesday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 5% mark based on its quarterly dividend (annualized to $4.28), with the stock changing hands as low as $85.37 on the day. AbbVie Inc (Symbol: ABBV) is an S&P 500 company,... | Looking at the universe of stocks we cover at Dividend Channel , in trading on Wednesday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 5% mark based on its quarterly dividend (annualized to $4.28), with the stock changing hands as low as $85.37 on the day. AbbVie Inc (Symbol: ABBV) is an S&P 500 company,... | Looking at the universe of stocks we cover at Dividend Channel , in trading on Wednesday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 5% mark based on its quarterly dividend (annualized to $4.28), with the stock changing hands as low as $85.37 on the day. AbbVie Inc (Symbol: ABBV) is an S&P 500 company,... | Looking at the universe of stocks we cover at Dividend Channel , in trading on Wednesday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 5% mark based on its quarterly dividend (annualized to $4.28), with the stock changing hands as low as $85.37 on the day. AbbVie Inc (Symbol: ABBV) is an S&P 500 company,... |
25,257 | 2018-11-20 00:00:00 UTC | AbbVie (ABBV) Stock Moves -1.55%: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-stock-moves-1.55%3A-what-you-should-know-2018-11-20 | null | null | In the latest trading session, AbbVie (ABBV) closed at $88.09, marking a -1.55% move from the previous day. This change was narrower than the S&P 500's 1.82% loss on the day. Elsewhere, the Dow lost 2.21%, while the tech-heavy Nasdaq lost 1.7%.
Heading into today, shares of the drugmaker had gained 6.18% over the past ... | In the latest trading session, AbbVie (ABBV) closed at $88.09, marking a -1.55% move from the previous day. Wall Street will be looking for positivity from ABBV as it approaches its next earnings report date. Any recent changes to analyst estimates for ABBV should also be noted by investors. | In the latest trading session, AbbVie (ABBV) closed at $88.09, marking a -1.55% move from the previous day. Wall Street will be looking for positivity from ABBV as it approaches its next earnings report date. Any recent changes to analyst estimates for ABBV should also be noted by investors. | In the latest trading session, AbbVie (ABBV) closed at $88.09, marking a -1.55% move from the previous day. Wall Street will be looking for positivity from ABBV as it approaches its next earnings report date. Any recent changes to analyst estimates for ABBV should also be noted by investors. | In the latest trading session, AbbVie (ABBV) closed at $88.09, marking a -1.55% move from the previous day. Wall Street will be looking for positivity from ABBV as it approaches its next earnings report date. Any recent changes to analyst estimates for ABBV should also be noted by investors. |
25,258 | 2018-11-20 00:00:00 UTC | 3 Top Large-Cap Stocks to Buy in November | ABBV | https://www.nasdaq.com/articles/3-top-large-cap-stocks-buy-november-2018-11-20 | null | null | Large-cap stocks typically provide investors with consistency and stability, two features investors are sorely lacking from the rest of the market these days. While not a guarantee against suffering whipsaws in volatility, large-cap stocks can provide investors with a bit more than a modicum of reassurance that they wi... | In the third quarter, for instance, AbbVie's hematology/oncology product sales eclipsed $1 billion for the three-month period, thanks to the strong performance of both Imbruvica and Venclexta. Three Motley Fool contributors selected AbbVie (NYSE: ABBV) , 3M (NYSE: MMM) , and Netflix (NASDAQ: NFLX) as large-cap stocks t... | Three Motley Fool contributors selected AbbVie (NYSE: ABBV) , 3M (NYSE: MMM) , and Netflix (NASDAQ: NFLX) as large-cap stocks to buy in November. Buy the fear George Budwell (AbbVie): AbbVie, the maker of the world's best-selling medicine, Humira, has had a particularly rough year in 2018. Despite strong earnings over ... | Three Motley Fool contributors selected AbbVie (NYSE: ABBV) , 3M (NYSE: MMM) , and Netflix (NASDAQ: NFLX) as large-cap stocks to buy in November. Despite strong earnings over the course of the first nine months of the year and management's decision to up the company's top-flight dividend yet again during the most recen... | Three Motley Fool contributors selected AbbVie (NYSE: ABBV) , 3M (NYSE: MMM) , and Netflix (NASDAQ: NFLX) as large-cap stocks to buy in November. Buy the fear George Budwell (AbbVie): AbbVie, the maker of the world's best-selling medicine, Humira, has had a particularly rough year in 2018. Despite strong earnings over ... |
25,259 | 2018-11-19 00:00:00 UTC | Should Value Investors Consider AbbVie (ABBV) Stock Now? | ABBV | https://www.nasdaq.com/articles/should-value-investors-consider-abbvie-abbv-stock-now-2018-11-19 | null | null | Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn't want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?
One way to find these companies is by looking ... | If anything, ABBV is toward the lower end of its range in the time period from a P/S metric, suggesting some level of undervalued trading-at least compared to historical norms. In particular, it is worth noting that the company has a Growth grade of A and a Momentum score of D. This gives ABBV a Zacks VGM score-or its ... | If we focus on the long-term PE trend, AbbVie's current PE level puts it below its midpoint over the past five years. You can see the consensus estimate trend and recent price action for the stock in the chart below: AbbVie Inc. Price and Consensus AbbVie Inc. Price and Consensus | AbbVie Inc. Quote This somewhat mixed... | Let's put AbbVie Inc.ABBV stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks: PE Ratio A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. Y... | Let's put AbbVie Inc.ABBV stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks: PE Ratio A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. R... |
25,260 | 2018-11-19 00:00:00 UTC | Vertex (VRTX) Gets Positive CHMP Opinion for Orkambi in Kids | ABBV | https://www.nasdaq.com/articles/vertex-vrtx-gets-positive-chmp-opinion-for-orkambi-in-kids-2018-11-19 | null | null | Vertex Pharmaceuticals Inc.VRTX announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval for expanded use of Orkambi. The opinion is given for Orkambi (lumacaftor/ivacaftor) to treat children with cystic fibrosis (CF) age... | Both AbbVie ABBV and Galapagos NV's GLPG were jointly developing CF product candidates, which included a triple regimen combination. However, last month, AbbVie announced that it is taking full commercial and development responsibility of all clinical/pre-clinical programs in cystic fibrosis products, which were origin... | Both AbbVie ABBV and Galapagos NV's GLPG were jointly developing CF product candidates, which included a triple regimen combination. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysi... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Corbus Pharmaceuticals Holdings, Inc. (CRBP): Free Stock Analysis Report To read this article on Zacks.com click here. Both ... | Both AbbVie ABBV and Galapagos NV's GLPG were jointly developing CF product candidates, which included a triple regimen combination. However, last month, AbbVie announced that it is taking full commercial and development responsibility of all clinical/pre-clinical programs in cystic fibrosis products, which were origin... |
25,261 | 2018-11-18 00:00:00 UTC | Validea's Top Five Healthcare Stocks Based On John Neff - 11/18/2018 | ABBV | https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-john-neff-11182018-2018-11-18 | null | null | The following are the top rated Healthcare stocks according to Validea's Low PE Investor model based on the published strategy of John Neff . This strategy looks for firms with persistent earnings growth that trade at a discount relative to their earnings growth and dividend yield.
ABBVIE INC ( ABBV ) is a large-cap gr... | ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. As of December 31, 2016, the National Group included 84 hospitals, which were located in Alaska, California, Florida, southern Georgia, Idaho, I... | ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabet... | ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. Company Description: Medtronic Public Limited Company (Medtronic) is a medical technology and services company. | ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. Company Description: Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring techno... |
25,262 | 2018-11-17 00:00:00 UTC | Why Abbvie Is Down 5% in 2018 So Far | ABBV | https://www.nasdaq.com/articles/why-abbvie-down-5-2018-so-far-2018-11-17 | null | null | Buying up shares of AbbVie Inc. (NYSE: ABBV) at the beginning of 2018 seemed like a brilliant idea when the stock shot up 27% before the end of January, but that was simply the first leg of a long roller-coaster ride. By Nov. 1, 2018, AbbVie stock had fallen 35% from its peak earlier in the year and at recent prices, i... | The good news AbbVie began the year with a bang at the J.P. Morgan Healthcare Conference by sharing expectations for annual Humira sales that suggested they'll continue climbing to $21 billion by 2020. Rova-T's phase 3 flop was especially disappointing because AbbVie ignored lackluster early data and spent $5.8 billion... | A pipeline ready to deliver Earlier this year, AbbVie launched Orilissa, the first new treatment for endometriosis-associated pain in over a decade, and it recently took another big step. Buying up shares of AbbVie Inc. (NYSE: ABBV) at the beginning of 2018 seemed like a brilliant idea when the stock shot up 27% before... | The good news AbbVie began the year with a bang at the J.P. Morgan Healthcare Conference by sharing expectations for annual Humira sales that suggested they'll continue climbing to $21 billion by 2020. Momenta Pharmaceuticals (NASDAQ: MNTA) recently became the sixth drugmaker to delay the U.S. launch of its biosimilar ... | Buying up shares of AbbVie Inc. (NYSE: ABBV) at the beginning of 2018 seemed like a brilliant idea when the stock shot up 27% before the end of January, but that was simply the first leg of a long roller-coaster ride. By Nov. 1, 2018, AbbVie stock had fallen 35% from its peak earlier in the year and at recent prices, i... |
25,263 | 2018-11-15 00:00:00 UTC | After Hours Most Active for Nov 15, 2018 : QQQ, T, MSFT, GE, INTC, NVDA, ABBV, DWDP, HAL, FCX, CSCO, AMD | ABBV | https://www.nasdaq.com/articles/after-hours-most-active-nov-15-2018-qqq-t-msft-ge-intc-nvda-abbv-dwdp-hal-fcx-csco-amd | null | null | The NASDAQ 100 After Hours Indicator is down -34.04 to 6,856.41. The total After hours volume is currently 51,252,404 shares traded.
The following are the most active stocks for the after hours session :
Invesco QQQ Trust, Series 1 ( QQQ ) is -0.58 at $167.51, with 4,564,939 shares traded. This represents a 11.58% incr... | RTT News Reports: NVIDIA Corporation Q3 adjusted earnings Beat Estimates AbbVie Inc. ( ABBV ) is +0.01 at $90.15, with 1,589,357 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2019. ABBV's current last sale is 92.94% of the target price ... | RTT News Reports: NVIDIA Corporation Q3 adjusted earnings Beat Estimates AbbVie Inc. ( ABBV ) is +0.01 at $90.15, with 1,589,357 shares traded. ABBV's current last sale is 92.94% of the target price of $97. Over the last four weeks they have had 6 up revisions for the earnings forecast, for the fiscal quarter ending De... | RTT News Reports: NVIDIA Corporation Q3 adjusted earnings Beat Estimates AbbVie Inc. ( ABBV ) is +0.01 at $90.15, with 1,589,357 shares traded. ABBV's current last sale is 92.94% of the target price of $97. Over the last four weeks they have had 6 up revisions for the earnings forecast, for the fiscal quarter ending De... | RTT News Reports: NVIDIA Corporation Q3 adjusted earnings Beat Estimates AbbVie Inc. ( ABBV ) is +0.01 at $90.15, with 1,589,357 shares traded. ABBV's current last sale is 92.94% of the target price of $97. The NASDAQ 100 After Hours Indicator is down -34.04 to 6,856.41. |
25,264 | 2018-11-14 00:00:00 UTC | IWF, KO, PEP, ABBV: ETF Inflow Alert | ABBV | https://www.nasdaq.com/articles/iwf-ko-pep-abbv-etf-inflow-alert-2018-11-14 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 Growth ETF (Symbol: IWF) where we have detected an approximate $84.8 million dollar inflow -- that's a 0.2% increase week over week in outstanding units (from 285,750,0... | Among the largest underlying components of IWF, in trading today Coca-Cola Co (Symbol: KO) is off about 0.2%, PepsiCo Inc (Symbol: PEP) is trading flat, and AbbVie Inc (Symbol: ABBV) is lower by about 1.7%. For a complete list of holdings, visit the IWF Holdings page » The chart below shows the one year price performan... | Among the largest underlying components of IWF, in trading today Coca-Cola Co (Symbol: KO) is off about 0.2%, PepsiCo Inc (Symbol: PEP) is trading flat, and AbbVie Inc (Symbol: ABBV) is lower by about 1.7%. For a complete list of holdings, visit the IWF Holdings page » The chart below shows the one year price performan... | Among the largest underlying components of IWF, in trading today Coca-Cola Co (Symbol: KO) is off about 0.2%, PepsiCo Inc (Symbol: PEP) is trading flat, and AbbVie Inc (Symbol: ABBV) is lower by about 1.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , on... | Among the largest underlying components of IWF, in trading today Coca-Cola Co (Symbol: KO) is off about 0.2%, PepsiCo Inc (Symbol: PEP) is trading flat, and AbbVie Inc (Symbol: ABBV) is lower by about 1.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , on... |
25,265 | 2018-11-14 00:00:00 UTC | AbbVie (ABBV) Gains As Market Dips: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-gains-as-market-dips%3A-what-you-should-know-2018-11-14 | null | null | AbbVie (ABBV) closed at $88.31 in the latest trading session, marking a +0.1% move from the prior day. The stock outpaced the S&P 500's daily loss of 0.76%. At the same time, the Dow lost 0.82%, and the tech-heavy Nasdaq lost 0.9%.
Coming into today, shares of the drugmaker had lost 4.01% in the past month. In that sam... | AbbVie (ABBV) closed at $88.31 in the latest trading session, marking a +0.1% move from the prior day. ABBV will be looking to display strength as it nears its next earnings release, which is expected to be January 25, 2019. On that day, ABBV is projected to report earnings of $1.92 per share, which would represent yea... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie (ABBV) closed at $88.31 in the latest trading session, marking a +0.1% move from the prior day. ABBV will be looking to display strength as it nears its next earnings release, which is expec... | AbbVie (ABBV) closed at $88.31 in the latest trading session, marking a +0.1% move from the prior day. ABBV will be looking to display strength as it nears its next earnings release, which is expected to be January 25, 2019. On that day, ABBV is projected to report earnings of $1.92 per share, which would represent yea... | AbbVie (ABBV) closed at $88.31 in the latest trading session, marking a +0.1% move from the prior day. ABBV will be looking to display strength as it nears its next earnings release, which is expected to be January 25, 2019. On that day, ABBV is projected to report earnings of $1.92 per share, which would represent yea... |
25,266 | 2018-11-14 00:00:00 UTC | AbbVie's HCV Drug Mavyret Succeeds in Label Expansion Study | ABBV | https://www.nasdaq.com/articles/abbvies-hcv-drug-mavyret-succeeds-in-label-expansion-study-2018-11-14 | null | null | AbbVie, Inc.ABBV announced that its successful hepatitis C virus (HCV) medicine, Mavyret demonstrated high virologic cure rates in a study evaluating the 8-week, pan-genotypic, ribavirin-free, once-daily HCV treatment for an expanded patient population.
The phase IIIb EXPEDITION-8 study is evaluating Mavyret in treatme... | According to AbbVie, it may be used in up to 95% of HCV patients, depending on the stage of liver disease and prior treatment history. AbbVie, Inc.ABBV announced that its successful hepatitis C virus (HCV) medicine, Mavyret demonstrated high virologic cure rates in a study evaluating the 8-week, pan-genotypic, ribaviri... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie, Inc.ABBV announced that its s... | AbbVie, Inc.ABBV announced that its successful hepatitis C virus (HCV) medicine, Mavyret demonstrated high virologic cure rates in a study evaluating the 8-week, pan-genotypic, ribavirin-free, once-daily HCV treatment for an expanded patient population. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analy... | AbbVie, Inc.ABBV announced that its successful hepatitis C virus (HCV) medicine, Mavyret demonstrated high virologic cure rates in a study evaluating the 8-week, pan-genotypic, ribavirin-free, once-daily HCV treatment for an expanded patient population. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analy... |
25,267 | 2018-11-14 00:00:00 UTC | AstraZeneca to Sell US Rights of Lung Infection Drug to Sobi | ABBV | https://www.nasdaq.com/articles/astrazeneca-to-sell-us-rights-of-lung-infection-drug-to-sobi-2018-11-14 | null | null | AstraZeneca plcAZN announced an agreement to sell the U.S. rights of its pediatric lung infection medicine, Synagis to Swedish pharma company, Sobi for an upfront consideration of $1.5 billion plus further contingent payments.
About 130 AstraZeneca employees will also shift to Sobi as part of the transaction.
Shares of... | AstraZeneca's partner AbbVie, Inc. ABBV markets Synagis in over 80 countries outside the United States. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report To read this article on Zacks.com click here. AstraZeneca plcAZN announced an agreement t... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report To read this article on Zacks.com click here. AstraZeneca's partner AbbVie, Inc. ABBV markets Synagis in over 80 countries outside the United States. AstraZeneca plcAZN announced an agreement t... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report To read this article on Zacks.com click here. AstraZeneca's partner AbbVie, Inc. ABBV markets Synagis in over 80 countries outside the United States. AstraZeneca plcAZN announced an agreement t... | AstraZeneca's partner AbbVie, Inc. ABBV markets Synagis in over 80 countries outside the United States. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report To read this article on Zacks.com click here. The Synagis sale is the latest of the sever... |
25,268 | 2018-11-13 00:00:00 UTC | Better Buy: AbbVie Inc. vs. GlaxoSmithKline PLC | ABBV | https://www.nasdaq.com/articles/better-buy-abbvie-inc-vs-glaxosmithkline-plc-2018-11-13 | null | null | The trajectories for AbbVie (NYSE: ABBV) and GlaxoSmithKline (NYSE: GSK) stocks have been very different in recent years. While AbbVie generated big gains, GlaxoSmithKline (GSK) languished. The tables have been turned in 2018, though, with GSK outperforming AbbVie so far this year.
Which of these two big pharma stocks ... | AbbVie thinks it can obtain FDA approval for two new immunology drugs next year, risankizumab and upadacitinib. With a great dividend to boot, I think that AbbVie can deliver a market-beating return over the long run. *Stock Advisor returns as of August 6, 2018 Keith Speights owns shares of AbbVie and Gilead Sciences. | The trajectories for AbbVie (NYSE: ABBV) and GlaxoSmithKline (NYSE: GSK) stocks have been very different in recent years. While AbbVie generated big gains, GlaxoSmithKline (GSK) languished. The tables have been turned in 2018, though, with GSK outperforming AbbVie so far this year. | The trajectories for AbbVie (NYSE: ABBV) and GlaxoSmithKline (NYSE: GSK) stocks have been very different in recent years. The case for AbbVie Let's start with the biggest reason why not to buy AbbVie stock. While AbbVie generated big gains, GlaxoSmithKline (GSK) languished. | Better buy Although GlaxoSmithKline appears to be doing quite well right now, I think that AbbVie is the better pick. The trajectories for AbbVie (NYSE: ABBV) and GlaxoSmithKline (NYSE: GSK) stocks have been very different in recent years. While AbbVie generated big gains, GlaxoSmithKline (GSK) languished. |
25,269 | 2018-11-13 00:00:00 UTC | Health Care Sector Update for 11/13/2018: ABBV,VKTX,CRON,CRON.TO,VLRX | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-11132018-abbvvktxcroncrontovlrx-2018-11-13 | null | null | Top Health Care Stocks
JNJ -0.56%
PFE -1.56%
ABT -1.83%
MRK -0.41%
AMGN -0.07%
Health care stocks continue to trend lower today, including a slightly more than 0.6% decline for the NYSE Health Care Index in recent trade. Also, shares of health care companies in the S&P 500 were down just over 0.9% as a group while the ... | Among health care stocks moving on news: (-) AbbVie ( ABBV ) dropped as much as 1.5% on Tuesday despite the drugmaker reported new data demonstrating its Mavyret pan-genotypic chronic hepatitis C virus treatment produced a sustained virologic response 12 weeks after treatment in 100% of the cirrhosis patients with geno... | Among health care stocks moving on news: (-) AbbVie ( ABBV ) dropped as much as 1.5% on Tuesday despite the drugmaker reported new data demonstrating its Mavyret pan-genotypic chronic hepatitis C virus treatment produced a sustained virologic response 12 weeks after treatment in 100% of the cirrhosis patients with geno... | Among health care stocks moving on news: (-) AbbVie ( ABBV ) dropped as much as 1.5% on Tuesday despite the drugmaker reported new data demonstrating its Mavyret pan-genotypic chronic hepatitis C virus treatment produced a sustained virologic response 12 weeks after treatment in 100% of the cirrhosis patients with geno... | Among health care stocks moving on news: (-) AbbVie ( ABBV ) dropped as much as 1.5% on Tuesday despite the drugmaker reported new data demonstrating its Mavyret pan-genotypic chronic hepatitis C virus treatment produced a sustained virologic response 12 weeks after treatment in 100% of the cirrhosis patients with geno... |
25,270 | 2018-11-09 00:00:00 UTC | 6 Pharmaceutical Stocks to Buy After the Midterms | ABBV | https://www.nasdaq.com/articles/6-pharmaceutical-stocks-to-buy-after-the-midterms-2018-11-09 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Despite massive gains for the Democrats in the midterm elections in the House of Representatives and on the state level, the Republicans managed to hold onto the Senate. This is good for big pharmaceutical stocks (if bad for pharmaceutical users ). Had the ... | AbbVie (ABBV) Source: Shutterstock AbbVie Inc. (NYSE: ABBV ) recently hiked its dividend from $0.96 a share to $1.07. Adjusted operational sales grew 18.5%, thanks to strong performance of AbbVie's portfolio. ABBV now expects FY 2018 adjusted earnings coming in at $7.90 to $7.92 a share, which represents annual growth ... | AbbVie (ABBV) Source: Shutterstock AbbVie Inc. (NYSE: ABBV ) recently hiked its dividend from $0.96 a share to $1.07. Adjusted operational sales grew 18.5%, thanks to strong performance of AbbVie's portfolio. ABBV now expects FY 2018 adjusted earnings coming in at $7.90 to $7.92 a share, which represents annual growth ... | AbbVie (ABBV) Source: Shutterstock AbbVie Inc. (NYSE: ABBV ) recently hiked its dividend from $0.96 a share to $1.07. Adjusted operational sales grew 18.5%, thanks to strong performance of AbbVie's portfolio. ABBV now expects FY 2018 adjusted earnings coming in at $7.90 to $7.92 a share, which represents annual growth ... | Adjusted operational sales grew 18.5%, thanks to strong performance of AbbVie's portfolio. AbbVie (ABBV) Source: Shutterstock AbbVie Inc. (NYSE: ABBV ) recently hiked its dividend from $0.96 a share to $1.07. ABBV now expects FY 2018 adjusted earnings coming in at $7.90 to $7.92 a share, which represents annual growth ... |
25,271 | 2018-11-09 00:00:00 UTC | Pharma Stock Roundup: LLY, AZN Report Q3 Earnings, PFE Gets FDA Nod for Cancer Drug | ABBV | https://www.nasdaq.com/articles/pharma-stock-roundup%3A-lly-azn-report-q3-earnings-pfe-gets-fda-nod-for-cancer-drug-2018-11 | null | null | This week Lilly LLY and AstraZeneca AZN released their third-quarter 2018 results. Pfizer PFE gained FDA approval for a new cancer medicine, its third cancer drug approval in less than two months while Bristol-Myers BMY got a nod from the same regulatory body for a triplet cancer combination for multiple myeloma.
Recap... | AbbVie Settles With Momenta on Humira Biosimilar : AbbVie ABBV signed a non-exclusive licensing deal with Momenta regarding the latter's proposed biosimilar version of Humira. AbbVie has similar licensing deals with Amgen, Mylan, Sandoz and Biogen/Samsung Bioepis. Click to get this free report Merck & Co., Inc. (MRK): ... | Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report Sanofi (SNY): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysi... | Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report Sanofi (SNY): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysi... | AbbVie Settles With Momenta on Humira Biosimilar : AbbVie ABBV signed a non-exclusive licensing deal with Momenta regarding the latter's proposed biosimilar version of Humira. AbbVie has similar licensing deals with Amgen, Mylan, Sandoz and Biogen/Samsung Bioepis. Click to get this free report Merck & Co., Inc. (MRK): ... |
25,272 | 2018-11-09 00:00:00 UTC | Momenta (MNTA) Reports Narrower-Than-Expected Loss in Q3 | ABBV | https://www.nasdaq.com/articles/momenta-mnta-reports-narrower-than-expected-loss-in-q3-2018-11-09 | null | null | Shares of Momenta Pharmaceuticals Inc. MNTA gained 0.5% after the company reported mixed results for the third quarter.
Momenta's stock has gained 4% in the year so far, against the industry's decline of 14.3%.
The company reported loss per share of 45 cents in the quarter (excluding restructuring charges), narrower th... | Pipeline Updates As a result of its strategic review (results announced in October 2018), Momenta plans to advance its two late-stage biosimilar assets, M923, which is its wholly-owned proposed biosimilar to AbbVie's ABBV Humira, and M710, which is its proposed biosimilar to Regeneron's Eylea being developed in collabo... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Momenta Pharmaceuticals, Inc. (MNTA): Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. Pipeline Updates... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Momenta Pharmaceuticals, Inc. (MNTA): Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. Pipeline Updates... | Pipeline Updates As a result of its strategic review (results announced in October 2018), Momenta plans to advance its two late-stage biosimilar assets, M923, which is its wholly-owned proposed biosimilar to AbbVie's ABBV Humira, and M710, which is its proposed biosimilar to Regeneron's Eylea being developed in collabo... |
25,273 | 2018-11-08 00:00:00 UTC | AbbVie (ABBV) Gains As Market Dips: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-gains-as-market-dips%3A-what-you-should-know-2018-11-08 | null | null | In the latest trading session, AbbVie (ABBV) closed at $87.73, marking a +0.89% move from the previous day. This move outpaced the S&P 500's daily loss of 0.25%. Meanwhile, the Dow gained 0.04%, and the Nasdaq, a tech-heavy index, lost 0.53%.
Heading into today, shares of the drugmaker had lost 6.58% over the past mont... | In the latest trading session, AbbVie (ABBV) closed at $87.73, marking a +0.89% move from the previous day. ABBV's full-year Zacks Consensus Estimates are calling for earnings of $7.92 per share and revenue of $32.78 billion. ABBV will be looking to display strength as it nears its next earnings release, which is expec... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. In the latest trading session, AbbVie (ABBV) closed at $87.73, marking a +0.89% move from the previous day. ABBV will be looking to display strength as it nears its next earnings release, which is ... | ABBV's full-year Zacks Consensus Estimates are calling for earnings of $7.92 per share and revenue of $32.78 billion. In the latest trading session, AbbVie (ABBV) closed at $87.73, marking a +0.89% move from the previous day. ABBV will be looking to display strength as it nears its next earnings release, which is expec... | In the latest trading session, AbbVie (ABBV) closed at $87.73, marking a +0.89% move from the previous day. ABBV currently has a Zacks Rank of #3 (Hold). ABBV will be looking to display strength as it nears its next earnings release, which is expected to be January 25, 2019. |
25,274 | 2018-11-07 00:00:00 UTC | Better Buy: Eli Lilly and Company vs. AbbVie Inc. | ABBV | https://www.nasdaq.com/articles/better-buy-eli-lilly-and-company-vs-abbvie-inc-2018-11-07 | null | null | Over the past six months, shares of Eli Lilly and Company (NYSE: LLY) and AbbVie Inc. (NYSE: ABBV) have been traveling in opposite directions that might seem a bit bizarre on the surface. AbbVie has reported much faster growth on the top and bottom lines than Lilly, but AbbVie's stock price fell 13% while Eli Lilly's r... | While Lilly's dividend program has limped along over the past five years, AbbVie raised its payout a stunning 168%, and investors can expect the 4.9% yield the stock offers at recent prices to continue rising in the near term. Over the past six months, shares of Eli Lilly and Company (NYSE: LLY) and AbbVie Inc. (NYSE: ... | While Lilly's dividend program has limped along over the past five years, AbbVie raised its payout a stunning 168%, and investors can expect the 4.9% yield the stock offers at recent prices to continue rising in the near term. Over the past six months, shares of Eli Lilly and Company (NYSE: LLY) and AbbVie Inc. (NYSE: ... | AbbVie has reported much faster growth on the top and bottom lines than Lilly, but AbbVie's stock price fell 13% while Eli Lilly's rocketed 41% higher. While Lilly's dividend program has limped along over the past five years, AbbVie raised its payout a stunning 168%, and investors can expect the 4.9% yield the stock of... | Over the past six months, shares of Eli Lilly and Company (NYSE: LLY) and AbbVie Inc. (NYSE: ABBV) have been traveling in opposite directions that might seem a bit bizarre on the surface. AbbVie has reported much faster growth on the top and bottom lines than Lilly, but AbbVie's stock price fell 13% while Eli Lilly's r... |
25,275 | 2018-11-07 00:00:00 UTC | 7 Healthcare Stocks Soaring on Election Results | ABBV | https://www.nasdaq.com/articles/7-healthcare-stocks-soaring-election-results-2018-11-07 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
U.S. equities are surging strongly on Wednesday as the Democrats emerged with a narrow majority in the House of Representatives following a bitter mid-term election contest. The Republicans expanded their majority in the Senate. The outcome should be a mix ... | Healthcare Stocks to Buy: AbbVie (ABBV) Shares of AbbVie (NYSE: ABBV ) are climbing back up and over their 20-day moving average in what looks like an attempt to return to the trading range that has prevailed for most of the year to date - centered around the $95-a-share level. But above all this, the Democrats' ran on... | Healthcare Stocks to Buy: AbbVie (ABBV) Shares of AbbVie (NYSE: ABBV ) are climbing back up and over their 20-day moving average in what looks like an attempt to return to the trading range that has prevailed for most of the year to date - centered around the $95-a-share level. 10 Strong Buy Stocks Trading at Killer En... | Healthcare Stocks to Buy: AbbVie (ABBV) Shares of AbbVie (NYSE: ABBV ) are climbing back up and over their 20-day moving average in what looks like an attempt to return to the trading range that has prevailed for most of the year to date - centered around the $95-a-share level. 10 Strong Buy Stocks Trading at Killer En... | Healthcare Stocks to Buy: AbbVie (ABBV) Shares of AbbVie (NYSE: ABBV ) are climbing back up and over their 20-day moving average in what looks like an attempt to return to the trading range that has prevailed for most of the year to date - centered around the $95-a-share level. 10 Strong Buy Stocks Trading at Killer En... |
25,276 | 2018-11-06 00:00:00 UTC | Notable ETF Inflow Detected - DGRO, PFE, ABBV, CMCSA | ABBV | https://www.nasdaq.com/articles/notable-etf-inflow-detected-dgro-pfe-abbv-cmcsa-2018-11-06 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core Dividend Growth ETF (Symbol: DGRO) where we have detected an approximate $222.0 million dollar inflow -- that's a 4.9% increase week over week in outstanding units (from 127,85... | Among the largest underlying components of DGRO, in trading today Pfizer Inc (Symbol: PFE) is down about 0.2%, AbbVie Inc (Symbol: ABBV) is up about 0.8%, and Comcast Corp (Symbol: CMCSA) is lower by about 0.2%. For a complete list of holdings, visit the DGRO Holdings page » The chart below shows the one year price per... | Among the largest underlying components of DGRO, in trading today Pfizer Inc (Symbol: PFE) is down about 0.2%, AbbVie Inc (Symbol: ABBV) is up about 0.8%, and Comcast Corp (Symbol: CMCSA) is lower by about 0.2%. For a complete list of holdings, visit the DGRO Holdings page » The chart below shows the one year price per... | Among the largest underlying components of DGRO, in trading today Pfizer Inc (Symbol: PFE) is down about 0.2%, AbbVie Inc (Symbol: ABBV) is up about 0.8%, and Comcast Corp (Symbol: CMCSA) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel... | Among the largest underlying components of DGRO, in trading today Pfizer Inc (Symbol: PFE) is down about 0.2%, AbbVie Inc (Symbol: ABBV) is up about 0.8%, and Comcast Corp (Symbol: CMCSA) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel... |
25,277 | 2018-11-02 00:00:00 UTC | AbbVie's (ABBV) Q3 Earnings Beat Estimates, 2018 EPS View Up | ABBV | https://www.nasdaq.com/articles/abbvies-abbv-q3-earnings-beat-estimates-2018-eps-view-up-2018-11-02 | null | null | AbbVie Inc.ABBV posted better-than-expected third-quarter 2018 earnings while its revenues missed estimates by a slight margin. Moreover, the company raised its expectations for 2018 bottom line. Shares rose almost 3.4% in pre-market.
Shares of AbbVie have declined 17.1% in a year's time against the industry 's 5% rise... | AbbVie Inc.ABBV posted better-than-expected third-quarter 2018 earnings while its revenues missed estimates by a slight margin. Shares of AbbVie have declined 17.1% in a year's time against the industry 's 5% rise. AbbVie logged $160 million of international profit sharing with Johnson & Johnson JNJ . | Price, Consensus and EPS Surprise Price, Consensus and EPS Surprise | Quote Zacks Rank AbbVie currently carries a Zacks Rank #3 (Hold). Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Abb... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc.ABBV posted better-than-expected th... | AbbVie Inc.ABBV posted better-than-expected third-quarter 2018 earnings while its revenues missed estimates by a slight margin. Shares of AbbVie have declined 17.1% in a year's time against the industry 's 5% rise. AbbVie logged $160 million of international profit sharing with Johnson & Johnson JNJ . |
25,278 | 2018-11-02 00:00:00 UTC | AbbVie Stock Jumps Higher on Q3 Earnings Beat | ABBV | https://www.nasdaq.com/articles/abbvie-stock-jumps-higher-q3-earnings-beat-2018-11-02 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
AbbVie stock got a slight boost on Friday following the release of its earnings report for the third quarter of 2018.
Source: Shutterstock
AbbVie (NYSE: ABBV ) reported earnings per share of $2.14 for the third quarter of the year. This is an increase over ... | It is also good news for AbbVie stock by just barely beating out analysts' revenue estimate of $8.23 billion for the period. Marijuana Stocks to Buy for the Midterm Elections AbbVie's most recent earnings report also sees the company updating its outlook for the full year of 2018. Compare Brokers The post AbbVie Stock ... | AbbVie's earnings report for the third quarter of the year also includes operating income of $3.16 billion. It is also good news for AbbVie stock by just barely beating out analysts' revenue estimate of $8.23 billion for the period. InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie stock got a sligh... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie stock got a slight boost on Friday following the release of its earnings report for the third quarter of 2018. AbbVie's earnings report for the third quarter of the year also includes operating income of $3.16 billion. Source: Shutterstock AbbVie (NY... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie stock got a slight boost on Friday following the release of its earnings report for the third quarter of 2018. Source: Shutterstock AbbVie (NYSE: ABBV ) reported earnings per share of $2.14 for the third quarter of the year. It is also a boon to AbbV... |
25,279 | 2018-11-02 00:00:00 UTC | AbbVie (ABBV) Tops Q3 Earnings Estimates | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-tops-q3-earnings-estimates-2018-11-02 | null | null | AbbVie (ABBV) came out with quarterly earnings of $2.14 per share, beating the Zacks Consensus Estimate of $2.01 per share. This compares to earnings of $1.41 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 6.47%. A quarter ago, it was e... | AbbVie (ABBV) came out with quarterly earnings of $2.14 per share, beating the Zacks Consensus Estimate of $2.01 per share. AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $8.24 billion for the quarter ended September 2018, missing the Zacks Consensus Estimate by 0.28%. AbbVie ... | AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $8.24 billion for the quarter ended September 2018, missing the Zacks Consensus Estimate by 0.28%. AbbVie (ABBV) came out with quarterly earnings of $2.14 per share, beating the Zacks Consensus Estimate of $2.01 per share. AbbVie ... | AbbVie (ABBV) came out with quarterly earnings of $2.14 per share, beating the Zacks Consensus Estimate of $2.01 per share. AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $8.24 billion for the quarter ended September 2018, missing the Zacks Consensus Estimate by 0.28%. AbbVie ... | AbbVie (ABBV) came out with quarterly earnings of $2.14 per share, beating the Zacks Consensus Estimate of $2.01 per share. AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $8.24 billion for the quarter ended September 2018, missing the Zacks Consensus Estimate by 0.28%. AbbVie ... |
25,280 | 2018-11-02 00:00:00 UTC | Pharma Stock Roundup: PFE, AGN Q3 Earnings, LLY, NVS Collaboration Deals in Focus | ABBV | https://www.nasdaq.com/articles/pharma-stock-roundup%3A-pfe-agn-q3-earnings-lly-nvs-collaboration-deals-in-focus-2018-11-02 | null | null | It was another busy week for the pharma sector, marked by earnings of bigwigs like Pfizer PFE , Allergan AGN , Sanofi SNY and Glaxo GSK . Merck MRK and AbbVie ABBV gained regulatory approvals for label expansion of their key cancer drugs. Eli Lilly LLY , Pfizer and Sanofi announced collaboration deals.
Recap of the Wee... | Merck MRK and AbbVie ABBV gained regulatory approvals for label expansion of their key cancer drugs. AbbVie Gets EU Approval for Venclexta and Rituxan Combo: AbbVie received European Commission's (EC) marketing approval for use of Venclexta in combination with Roche's MabThera (rituximab) for the treatment of patients ... | Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Sanofi (SNY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis R... | AbbVie Gets EU Approval for Venclexta and Rituxan Combo: AbbVie received European Commission's (EC) marketing approval for use of Venclexta in combination with Roche's MabThera (rituximab) for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia ("CLL") who have received at least one prior th... | Merck MRK and AbbVie ABBV gained regulatory approvals for label expansion of their key cancer drugs. AbbVie Gets EU Approval for Venclexta and Rituxan Combo: AbbVie received European Commission's (EC) marketing approval for use of Venclexta in combination with Roche's MabThera (rituximab) for the treatment of patients ... |
25,281 | 2018-11-02 00:00:00 UTC | Earnings Reaction History: AbbVie Inc., 63.6% Follow-Through Indicator, 4.0% Sensitive | ABBV | https://www.nasdaq.com/articles/earnings-reaction-history-abbvie-inc-636-follow-through-indicator-40-sensitive-2018-11-02 | null | null | Expected Earnings Release: 11/02/2018, Premarket
Avg. Extended-Hours Dollar Volume: $7,550,687
AbbVie Inc. ( ABBV ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Given its history, traders can expect very active trading in the issue immediately following its quarterly earnings an... | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 83.3% Average next regular session additional gain: 3.1% Over the prior three fiscal years (12 quarters), when shares of ABBV rose in the extended-hours session in reaction to its earnings announcement, history shows that 83.3% of... | Historical earnings event related premarket and after-hours trading activity in ABBV indicates that the price change in the extended hours is likely to be of significant value in forecasting additional price movement by the following regular session close. Last 12 Qtrs Positive Only Price Reactions Percent of time adde... | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 83.3% Average next regular session additional gain: 3.1% Over the prior three fiscal years (12 quarters), when shares of ABBV rose in the extended-hours session in reaction to its earnings announcement, history shows that 83.3% of... | Extended-Hours Dollar Volume: $7,550,687 AbbVie Inc. ( ABBV ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Historical earnings event related premarket and after-hours trading activity in ABBV indicates that the price change in the extended hours is likely to be of significant va... |
25,282 | 2018-11-02 00:00:00 UTC | 5 Income Stocks for Massive Payouts and Steady Growth | ABBV | https://www.nasdaq.com/articles/5-income-stocks-massive-payouts-and-steady-growth-2018-11-02 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Although many investors like to follow equities for potential stock price increases, a large number also choose to focus on income stocks . Some stocks offer cash payouts compelling enough to make dividend stocks the stocks to buy. This is especially true f... | But with an almost-single-digit PE ratio, double-digit profit growth, and a large, growing dividend, long-term investors should earn both income and gains by buying into ABBV stock. As such, these five income stocks offer higher than average dividends as well as the potential for stock price growth: AbbVie, Inc. (ABBV)... | As such, these five income stocks offer higher than average dividends as well as the potential for stock price growth: AbbVie, Inc. (ABBV) Source: Shutterstock AbbVie (NYSE: ABBV ) spun off from Abbott Laboratories (NYSE: ABT ) in 2013. But with an almost-single-digit PE ratio, double-digit profit growth, and a large, ... | As such, these five income stocks offer higher than average dividends as well as the potential for stock price growth: AbbVie, Inc. (ABBV) Source: Shutterstock AbbVie (NYSE: ABBV ) spun off from Abbott Laboratories (NYSE: ABT ) in 2013. Best known for the drug Humira, ABBV continues to develop and introduce new drugs a... | As such, these five income stocks offer higher than average dividends as well as the potential for stock price growth: AbbVie, Inc. (ABBV) Source: Shutterstock AbbVie (NYSE: ABBV ) spun off from Abbott Laboratories (NYSE: ABT ) in 2013. Best known for the drug Humira, ABBV continues to develop and introduce new drugs a... |
25,283 | 2018-11-02 00:00:00 UTC | AbbVie's Q3 Update: 3 Things You Need to Know | ABBV | https://www.nasdaq.com/articles/abbvies-q3-update-3-things-you-need-know-2018-11-02 | null | null | Investors can be fickle when it comes to AbbVie (NYSE: ABBV) . The big pharma company reported great Q2 results in July, but AbbVie's share price dropped anyway. You might think the company would have to really hit the ball out of the park with its third-quarter results to cause its stock to rise.
AbbVie pretty much di... | AbbVie CEO Richard Gonzalez said that the company was "particularly pleased" with the franchise's progress, adding that it's "now delivering revenue in excess of $1 billion per quarter and is poised for continued strong growth next year and beyond." The company's net other expenses not associated with operational costs... | Strong revenue growth -- but Humira wasn't the star AbbVie's Q3 revenue jumped 17.8% year over year to $8.24 billion. AbbVie announced adjusted diluted earnings per share (EPS) of $2.14. This lower tax expense accounted for 40% of AbbVie's GAAP earnings year-over-year increase. | Strong revenue growth -- but Humira wasn't the star AbbVie's Q3 revenue jumped 17.8% year over year to $8.24 billion. AbbVie CEO Richard Gonzalez said that the company was "particularly pleased" with the franchise's progress, adding that it's "now delivering revenue in excess of $1 billion per quarter and is poised for... | Strong revenue growth -- but Humira wasn't the star AbbVie's Q3 revenue jumped 17.8% year over year to $8.24 billion. AbbVie's adjusted EPS improvement was also helped by share buybacks, which lowered the company's weighted-average diluted shares outstanding by 5.5% year over year. Investors can be fickle when it comes... |
25,284 | 2018-11-01 00:00:00 UTC | Interesting ABBV Put And Call Options For December 14th | ABBV | https://www.nasdaq.com/articles/interesting-abbv-put-and-call-options-december-14th-2018-11-01 | null | null | Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the December 14th expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ABBV options chain for the new December 14th contracts and identified one put and one call contract of particular interest.
The put c... | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the... | Below is a chart showing ABBV's trailing twelve month trading history, with the $79.50 strike highlighted in red: Considering the fact that the $79.50 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possi... | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $78.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $79.50 strike price has a current bid of $2.78. Below is a chart showing ABBV'... | At Stock Options Channel , our YieldBoost formula has looked up and down the ABBV options chain for the new December 14th contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $79.50 strike highlighted in red: Consi... |
25,285 | 2018-11-01 00:00:00 UTC | Pre-Market Earnings Report for November 2, 2018 : XOM, CVX, BABA, ABBV, DUK, ENB, IMO, WLTW, FTS, CBOE, VST, STX | ABBV | https://www.nasdaq.com/articles/pre-market-earnings-report-november-2-2018-xom-cvx-baba-abbv-duk-enb-imo-wltw-fts-cboe-vst | null | null | The following companies are expected to report earnings prior to market open on 11/02/2018. Visit our Earnings Calendar for a full list of expected earnings releases.
Exxon Mobil Corporation ( XOM ) is reporting for the quarter ending September 30, 2018. The oil company's consensus earnings per share forecast from the ... | AbbVie Inc. ( ABBV ) is reporting for the quarter ending September 30, 2018. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2018 Price to Earnings ratio for ABBV is 9.90 vs. an industry ratio of 15.30. | AbbVie Inc. ( ABBV ) is reporting for the quarter ending September 30, 2018. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2018 Price to Earnings ratio for ABBV is 9.90 vs. an industry ratio of 15.30. | AbbVie Inc. ( ABBV ) is reporting for the quarter ending September 30, 2018. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2018 Price to Earnings ratio for ABBV is 9.90 vs. an industry ratio of 15.30. | In the past year ABBV has beat the expectations every quarter. AbbVie Inc. ( ABBV ) is reporting for the quarter ending September 30, 2018. Zacks Investment Research reports that the 2018 Price to Earnings ratio for ABBV is 9.90 vs. an industry ratio of 15.30. |
25,286 | 2018-10-31 00:00:00 UTC | Noteworthy Wednesday Option Activity: DVA, GOGO, ABBV | ABBV | https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity-dva-gogo-abbv-2018-10-31 | null | null | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in DaVita Inc (Symbol: DVA), where a total of 6,422 contracts have traded so far, representing approximately 642,200 underlying shares. That amounts to about 41.1% of DVA's average daily trading volume over the pas... | Particularly high volume was seen for the $79 strike put option expiring November 02, 2018 , with 3,766 contracts trading so far today, representing approximately 376,600 underlying shares of ABBV. Below is a chart showing GOGO's trailing twelve month trading history, with the $5 strike highlighted in orange: And AbbVi... | Below is a chart showing GOGO's trailing twelve month trading history, with the $5 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 23,170 contracts, representing approximately 2.3 million underlying shares or approximately 40.8% of ABBV's average daily trading volume over the p... | Below is a chart showing GOGO's trailing twelve month trading history, with the $5 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 23,170 contracts, representing approximately 2.3 million underlying shares or approximately 40.8% of ABBV's average daily trading volume over the p... | Below is a chart showing GOGO's trailing twelve month trading history, with the $5 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 23,170 contracts, representing approximately 2.3 million underlying shares or approximately 40.8% of ABBV's average daily trading volume over the p... |
25,287 | 2018-10-30 00:00:00 UTC | What's in the Cards for AbbVie (ABBV) This Earnings Season? | ABBV | https://www.nasdaq.com/articles/whats-in-the-cards-for-abbvie-abbv-this-earnings-season-2018-10-30 | null | null | AbbVie Inc.ABBV is scheduled to report third-quarter 2018 results on Nov 2, before market open. In the last reported quarter, the company delivered a positive earnings surprise of 1.01%.
Shares of AbbVie have declined 16.4% so far this year against the industry 's increase of 7%.
Notably, AbbVie's earnings history is q... | AbbVie's flagship product, Humira, which is approved for several inflammatory indications, continues to witness strong demand trends despite launch of drugs with new mechanisms of action and competition from indirect biosimilars. AbbVie's hepatitis C virus ("HCV") segment also showed impressive growth on the back of be... | AbbVie Inc. Price and EPS Surprise AbbVie Inc. Price and EPS Surprise | AbbVie Inc. Quote Stocks That Warrant a Look Here are some biotech stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat in their upcoming releases. Click to get this fre... | AbbVie Inc. Price and EPS Surprise AbbVie Inc. Price and EPS Surprise | AbbVie Inc. Quote Stocks That Warrant a Look Here are some biotech stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat in their upcoming releases. Click to get this fre... | AbbVie expects global sales of $725 million. AbbVie Inc.ABBV is scheduled to report third-quarter 2018 results on Nov 2, before market open. Shares of AbbVie have declined 16.4% so far this year against the industry 's increase of 7%. |
25,288 | 2018-10-30 00:00:00 UTC | Better Buy: Celgene Corporation vs. Gilead Sciences | ABBV | https://www.nasdaq.com/articles/better-buy-celgene-corporation-vs-gilead-sciences-2018-10-30 | null | null | It's been a terrifying month for biotech stocks across the board. The Nasdaq Biotechnology index has already tumbled 14% in October. That's brought some already attractive biotech stocks down to prices that are hard to ignore.
Shares of Celgene Corporation (NASDAQ: CELG) and Gilead Sciences Inc. (NASDAQ: GILD) have tum... | That's because Gilead and its development partner Galapagos (NASDAQ: GLPG) recently presented trial results that suggest filgotinib is on par with upadacitinib from AbbVie and Olumiant from Eli Lilly in terms of efficacy. Celgene's late-stage pipeline includes ozanimod, an oral multiple sclerosis and inflammatory bowel... | That's because Gilead and its development partner Galapagos (NASDAQ: GLPG) recently presented trial results that suggest filgotinib is on par with upadacitinib from AbbVie and Olumiant from Eli Lilly in terms of efficacy. The case for Celgene Corporation Celgene's lead product, Revlimid, is one of the world's best-sell... | That's because Gilead and its development partner Galapagos (NASDAQ: GLPG) recently presented trial results that suggest filgotinib is on par with upadacitinib from AbbVie and Olumiant from Eli Lilly in terms of efficacy. Shares of Celgene Corporation (NASDAQ: CELG) and Gilead Sciences Inc. (NASDAQ: GILD) have tumbled ... | That's because Gilead and its development partner Galapagos (NASDAQ: GLPG) recently presented trial results that suggest filgotinib is on par with upadacitinib from AbbVie and Olumiant from Eli Lilly in terms of efficacy. The biotech stock doesn't offer a dividend, but the company has been able to lower its outstanding... |
25,289 | 2018-10-29 00:00:00 UTC | 5 Dividend Aristocrats Where Analysts See Capital Gains | ABBV | https://www.nasdaq.com/articles/5-dividend-aristocrats-where-analysts-see-capital-gains-2018-10-29 | null | null | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention - and furthermore, "tracking" funds that follow ... | With all of this demand for shares, dividend growth stocks can sometimes become "fully priced," where there isn't much upside to analyst targets. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential: Anothe... | The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented. The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period - so the expected total ret... | But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. The average ... | But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. The recent s... |
25,290 | 2018-10-29 00:00:00 UTC | How The Parts Add Up: RNLC Targets $25 | ABBV | https://www.nasdaq.com/articles/how-parts-add-rnlc-targets-25-2018-10-29 | null | null | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Large Cap US Equity Select ETF... | Below is a twelve month price history chart comparing the stock performance of ARMK, NUE, and ABBV: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of RNLC's un... | Three of RNLC's underlying holdings with notable upside to their analyst target prices are Aramark (Symbol: ARMK), Nucor Corp. (Symbol: NUE), and AbbVie Inc (Symbol: ABBV). Similarly, NUE has 33.62% upside from the recent share price of $56.13 if the average analyst target price of $75.00/share is reached, and analysts... | Similarly, NUE has 33.62% upside from the recent share price of $56.13 if the average analyst target price of $75.00/share is reached, and analysts on average are expecting ABBV to reach a target price of $107.75/share, which is 33.37% above the recent price of $80.79. Below is a twelve month price history chart compar... | Similarly, NUE has 33.62% upside from the recent share price of $56.13 if the average analyst target price of $75.00/share is reached, and analysts on average are expecting ABBV to reach a target price of $107.75/share, which is 33.37% above the recent price of $80.79. Three of RNLC's underlying holdings with notable u... |
25,291 | 2018-10-27 00:00:00 UTC | AbbVie Takes Aim at Vertex Pharmaceuticals Incorporated | ABBV | https://www.nasdaq.com/articles/abbvie-takes-aim-vertex-pharmaceuticals-incorporated-2018-10-27 | null | null | At the moment, treatment options for cystic fibrosis are limited to drugs marketed by Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) , but a deep-pocketed drugmaker just took a big step toward entering the space. AbbVie, Inc. (NYSE: ABBV) recently acquired full control of a clinical-stage cystic fibrosis program from Galap... | AbbVie, Inc. (NYSE: ABBV) recently acquired full control of a clinical-stage cystic fibrosis program from Galapagos N.V. (NASDAQ: GLPG) . Vertex's attempts at a three-drug CF therapy are miles ahead of AbbVie's phase 1 program. Vertex's pricing power depends on a lack of viable alternatives, as AbbVie has proven in the... | Gilead Sciences ' (NASDAQ: GILD) sales in its hepatitis C antiviral franchise hit $19 billion in 2015 before AbbVie began fielding competing treatments at deep discounts in 2016. AbbVie, Inc. (NYSE: ABBV) recently acquired full control of a clinical-stage cystic fibrosis program from Galapagos N.V. (NASDAQ: GLPG) . Ver... | AbbVie, Inc. (NYSE: ABBV) recently acquired full control of a clinical-stage cystic fibrosis program from Galapagos N.V. (NASDAQ: GLPG) . Vertex's attempts at a three-drug CF therapy are miles ahead of AbbVie's phase 1 program. Vertex's pricing power depends on a lack of viable alternatives, as AbbVie has proven in the... | Gilead Sciences ' (NASDAQ: GILD) sales in its hepatitis C antiviral franchise hit $19 billion in 2015 before AbbVie began fielding competing treatments at deep discounts in 2016. AbbVie, Inc. (NYSE: ABBV) recently acquired full control of a clinical-stage cystic fibrosis program from Galapagos N.V. (NASDAQ: GLPG) . Ver... |
25,292 | 2018-10-27 00:00:00 UTC | Where Will Gilead Sciences, Inc. Be in 5 Years? | ABBV | https://www.nasdaq.com/articles/where-will-gilead-sciences-inc-be-5-years-2018-10-27 | null | null | Gilead Sciences (NASDAQ: GILD) is in a slump. Over the past three years, the biotech's stock has lost over 35% of its value, thanks to falling hepatitis C sales, generic competition entering the HIV market in key geographies, and a slate of setbacks in hematology/oncology.
To break out of this prolonged downturn, Gilea... | AbbVie also is far more familiar with the anti-inflammatory market than Gilead, which has been proven by the biotech's ability to repel nearly every major competitive threat to its flagship arthritis medication Humira for a sustained period of time. On the inflammation front, Gilead and partner Galapagos are angling to... | *Stock Advisor returns as of August 6, 2018 George Budwell owns shares of AbbVie, Atara Biotherapeutics, Celgene, Johnson & Johnson, Pfizer, and Viking Therapeutics. On the inflammation front, Gilead and partner Galapagos are angling to grab market share away from AbbVie (NYSE: ABBV) and Pfizer with their experimental ... | AbbVie also is far more familiar with the anti-inflammatory market than Gilead, which has been proven by the biotech's ability to repel nearly every major competitive threat to its flagship arthritis medication Humira for a sustained period of time. On the inflammation front, Gilead and partner Galapagos are angling to... | On the inflammation front, Gilead and partner Galapagos are angling to grab market share away from AbbVie (NYSE: ABBV) and Pfizer with their experimental JAK1 inhibitor, filgotinib. First and foremost, AbbVie decided to hand back the development rights to filgotinib to Galapagos in favor of its own internal candidate, ... |
25,293 | 2018-10-26 00:00:00 UTC | Pharma Stock Roundup: MRK, BMY Q3 Earnings, Cancer Data Presentations at ESMO | ABBV | https://www.nasdaq.com/articles/pharma-stock-roundup%3A-mrk-bmy-q3-earnings-cancer-data-presentations-at-esmo-2018-10-26 | null | null | This week was a relatively busy one for the pharma sector, marked by earnings of bigwigs like Merck MRK and Bristol Myers BMY . Early this week, several drug giants presented data from key cancer studies at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany.
Recap of the Week's Most Impor... | AbbVie's JAK1 inhibitor Meets Endpoints in Ulcerative Colitis Study: AbbVie ABBV announced that a phase IIb/III dose-ranging study (U-ACHIEVE) evaluating its investigational JAK1 inhibitor, upadacitinib for moderately-to-severely active ulcerative colitis, met the primary endpoint of clinical remission and all ranked s... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Repo... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Repo... | AbbVie's JAK1 inhibitor Meets Endpoints in Ulcerative Colitis Study: AbbVie ABBV announced that a phase IIb/III dose-ranging study (U-ACHIEVE) evaluating its investigational JAK1 inhibitor, upadacitinib for moderately-to-severely active ulcerative colitis, met the primary endpoint of clinical remission and all ranked s... |
25,294 | 2018-10-26 00:00:00 UTC | iShares Core Dividend Growth ETF Experiences Big Inflow | ABBV | https://www.nasdaq.com/articles/ishares-core-dividend-growth-etf-experiences-big-inflow-2018-10-26 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core Dividend Growth ETF (Symbol: DGRO) where we have detected an approximate $173.6 million dollar inflow -- that's a 4.1% increase week over week in outstanding units (from 122,65... | Among the largest underlying components of DGRO, in trading today AbbVie Inc (Symbol: ABBV) is down about 2.2%, PepsiCo Inc (Symbol: PEP) is off about 1.6%, and Boeing Co. (Symbol: BA) is lower by about 1.7%. For a complete list of holdings, visit the DGRO Holdings page » The chart below shows the one year price perfor... | Among the largest underlying components of DGRO, in trading today AbbVie Inc (Symbol: ABBV) is down about 2.2%, PepsiCo Inc (Symbol: PEP) is off about 1.6%, and Boeing Co. (Symbol: BA) is lower by about 1.7%. For a complete list of holdings, visit the DGRO Holdings page » The chart below shows the one year price perfor... | Among the largest underlying components of DGRO, in trading today AbbVie Inc (Symbol: ABBV) is down about 2.2%, PepsiCo Inc (Symbol: PEP) is off about 1.6%, and Boeing Co. (Symbol: BA) is lower by about 1.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , ... | Among the largest underlying components of DGRO, in trading today AbbVie Inc (Symbol: ABBV) is down about 2.2%, PepsiCo Inc (Symbol: PEP) is off about 1.6%, and Boeing Co. (Symbol: BA) is lower by about 1.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , ... |
25,295 | 2018-10-26 00:00:00 UTC | AbbVie (ABBV) Q3 Earnings Preview: What's Shaping Up? | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-q3-earnings-preview%3A-whats-shaping-up-2018-10-26 | null | null | The market expects AbbVie (ABBV) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2018. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock ... | The market expects AbbVie (ABBV) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2018. How Have the Numbers Shaped Up for AbbVie? For AbbVie, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have r... | The market expects AbbVie (ABBV) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2018. How Have the Numbers Shaped Up for AbbVie? For AbbVie, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have r... | The market expects AbbVie (ABBV) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2018. How Have the Numbers Shaped Up for AbbVie? For AbbVie, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have r... | For the last reported quarter, it was expected that AbbVie would post earnings of $1.98 per share when it actually produced earnings of $2, delivering a surprise of +1.01%. The market expects AbbVie (ABBV) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended ... |
25,296 | 2018-10-24 00:00:00 UTC | Healthcare ETFs to Buy Ahead of Q3 Earnings | ABBV | https://www.nasdaq.com/articles/healthcare-etfs-buy-ahead-q3-earnings-2018-10-24 | null | null | Healthcare was the best performing sector in the third quarter. The dual tailwinds of encouraging industry fundamentals and the sector's defensive tilt led to the rally in the sector. The wave of mergers and acquisitions also added to its strength (read: Top Performing ETFs of the Third Quarter ).
Popular ETFs like Hea... | The strength is likely to continue into the Q3 earnings season as some big names like Pfizer PFE , Merck MRK , Amgen AMGN , AbbVie ABBV , Gilead Sciences GILD and Bristol-Myers Squibb (BMY) are lined up to report this week and in the next. AbbVie has a Zacks Rank #3 and an Earnings ESP of -0.20%. Click to get this free... | The strength is likely to continue into the Q3 earnings season as some big names like Pfizer PFE , Merck MRK , Amgen AMGN , AbbVie ABBV , Gilead Sciences GILD and Bristol-Myers Squibb (BMY) are lined up to report this week and in the next. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Mer... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report VIPERS-HLTH CR (VHT): ETF Research Reports FID-H CARE (FHLC): ETF Research Reports SPDR-HLTH CR (XLV): ETF Research Reports ISHARS-US HLTHC (IYH)... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report VIPERS-HLTH CR (VHT): ETF Research Reports FID-H CARE (FHLC): ETF Research Reports SPDR-HLTH CR (XLV): ETF Research Reports ISHARS-US HLTHC (IYH)... |
25,297 | 2018-10-24 00:00:00 UTC | 3 Healthcare Stocks I'd Buy Right Now | ABBV | https://www.nasdaq.com/articles/3-healthcare-stocks-id-buy-right-now-2018-10-24 | null | null | Warren Buffett once said, "When it's raining gold, reach for a bucket, not a thimble." Believe it or not, it's raining gold right now. And that's especially the case for several great healthcare stocks.
What I mean is that the stock market's pullback is causing quite a few stocks to trade at attractive prices. Whether ... | Over the long run, AbbVie's current products (including Humira) and its pipeline candidates should allow the company to deliver solid total returns to investors. Three healthcare stocks I'd buy right now are AbbVie (NYSE: ABBV) , Celgene (NASDAQ: CELG) , and Teladoc Health (NYSE: TDOC) . AbbVie I like dividends -- and ... | Three healthcare stocks I'd buy right now are AbbVie (NYSE: ABBV) , Celgene (NASDAQ: CELG) , and Teladoc Health (NYSE: TDOC) . Over the long run, AbbVie's current products (including Humira) and its pipeline candidates should allow the company to deliver solid total returns to investors. AbbVie I like dividends -- and ... | Three healthcare stocks I'd buy right now are AbbVie (NYSE: ABBV) , Celgene (NASDAQ: CELG) , and Teladoc Health (NYSE: TDOC) . *Stock Advisor returns as of August 6, 2018 Keith Speights owns shares of AbbVie, Celgene, and Teladoc. AbbVie I like dividends -- and AbbVie claims one of the best dividends in healthcare. | AbbVie I like dividends -- and AbbVie claims one of the best dividends in healthcare. Three healthcare stocks I'd buy right now are AbbVie (NYSE: ABBV) , Celgene (NASDAQ: CELG) , and Teladoc Health (NYSE: TDOC) . AbbVie has increased its dividend by 140% since being spun off from Abbott Labs in 2013. |
25,298 | 2018-10-23 00:00:00 UTC | AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-dips-more-than-broader-markets%3A-what-you-should-know-2018-10-23 | null | null | AbbVie (ABBV) closed at $82.96 in the latest trading session, marking a -1.55% move from the prior day. This change lagged the S&P 500's daily loss of 0.55%. At the same time, the Dow lost 0.5%, and the tech-heavy Nasdaq lost 0.42%.
Coming into today, shares of the drugmaker had lost 9.79% in the past month. In that sa... | AbbVie (ABBV) closed at $82.96 in the latest trading session, marking a -1.55% move from the prior day. ABBV's full-year Zacks Consensus Estimates are calling for earnings of $7.86 per share and revenue of $32.90 billion. Wall Street will be looking for positivity from ABBV as it approaches its next earnings report dat... | AbbVie (ABBV) closed at $82.96 in the latest trading session, marking a -1.55% move from the prior day. Wall Street will be looking for positivity from ABBV as it approaches its next earnings report date. ABBV's full-year Zacks Consensus Estimates are calling for earnings of $7.86 per share and revenue of $32.90 billio... | ABBV's full-year Zacks Consensus Estimates are calling for earnings of $7.86 per share and revenue of $32.90 billion. AbbVie (ABBV) closed at $82.96 in the latest trading session, marking a -1.55% move from the prior day. Wall Street will be looking for positivity from ABBV as it approaches its next earnings report dat... | ABBV's full-year Zacks Consensus Estimates are calling for earnings of $7.86 per share and revenue of $32.90 billion. AbbVie (ABBV) closed at $82.96 in the latest trading session, marking a -1.55% move from the prior day. Wall Street will be looking for positivity from ABBV as it approaches its next earnings report dat... |
25,299 | 2018-10-23 00:00:00 UTC | Validea Joel Greenblatt Strategy Daily Upgrade Report - 10/23/2018 | ABBV | https://www.nasdaq.com/articles/validea-joel-greenblatt-strategy-daily-upgrade-report-10232018-2018-10-23 | null | null | The following are today's upgrades for Validea's Earnings Yield Investor model based on the published strategy of Joel Greenblatt . This value model looks for companies with high return on capital and earnings yields.
ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating acco... | ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The following are today's upgrades for Validea's Earnings Yield Investor model based on the published strategy of Joel Greenblatt . | ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The following are today's upgrades for Validea's Earnings Yield Investor model based on the published strategy of Joel Greenblatt . | ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Met... | Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. The following are today's upgrades for Validea's Earnings Yield Investor model based on the published strategy of Joel Greenblatt . |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.